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The Cytochromes P450 
The cytochromes P450 (P450) are a superfamily of heme-containing 
monooxygenases that play a major role in the oxidative metabolism of a number of 
exogenous and endogenous compounds [1]. Substrates of P450s include xenobiotics, 
pesticides, vitamins and hormones [2]. P450s catalyze a variety of reactions; however, 
the most common is substrate oxidation by the insertion of one oxygen atom. Most P450-
mediated reactions result in the detoxification of exogenous compounds via the formation 
of hydrophilic metabolites that can be readily excreted from the body. Because 
metabolism by P450s leads to a decrease in plasma concentration of the parent drug, 
P450s play an important role in drug bioavailability. Poor bioavailability is a major 
reason why compounds generated in the discovery phase fail to make it to the market. 
Thus, there is considerable interest in better prediction of clinical outcomes by using in 
vitro approaches to understand P450-catalyzed reactions.  
The completion of the sequencing of the human genome has revealed that there 
are 57 human P450s [3], which are grouped into families (1, 2, 3, …) and subfamilies (A, 
B, C, …) based upon sequence homology. Individual P450s are then given a second 
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number, resulting in a unique name for each enzyme, e.g., 1A1, 1B1 or 2C9. The 
majority of P450s in humans are believed to be involved in the biosynthesis of 
endogenous compounds. The remaining P450s, in families 1-3, are involved the 
metabolism of xenobiotics. Figure 1.1 illustrates the relative contributions of P450s in 
drug metabolism overall. The majority of drug-metabolizing P450s are found in the liver 
embedded in the membrane of the endoplasmic reticulum; however, there are a number 
of P450s that are also expressed in extrahepatic tissues [4]. 
Unlike many enzymes which have strict substrate selectivity, P450s can bind and 
metabolize a diverse group of substrates which differ in size, shape and stereochemistry. 
A major challenge is to understand how individual P450s accommodate structurally 
unrelated substrates and oxidize these substrates in a stereo- and regio-specific manner 
[5]. Individual P450s have been shown to adopt multiple conformations in response to 
various ligands [6]. The structures of a number of mammalian and bacterial P450s have 
been solved and reveal that P450s contain several common structural elements including 
a series of helices denoted by letters A through L [7]. The A helix is closest to the N-
terminus of the catalytic domain [7]. Site-directed mutagenesis studies have indicated that 
residues in helices B, F and I contact the substrate [8]. There are also six well-conserved 
substrate recognition sequences that are present in most P450s [9].   
The major events involved in the P450 catalytic cycle are shown in Figure 1.2. At 
the beginning of the cycle, the P450 heme iron is in the ferric state (A). In the first step, 
the substrate binds to the P450, resulting in the transition of the iron from a low-spin to a 
high-spin state (B). An electron is then transferred from NADPH via NADPH-P450 


















Figure 1.1 – Phase I metabolism of xenobiotics [10]. The percentage of phase I 
metabolism of drugs that each enzyme contributes is estimated by the relative size of 
each section of the corresponding chart. P450s (denoted as CYPs in the figure) constitute 

































Figure 1.2 – The P450 catalytic cycle. The steps of the catalytic cycle are shown as 
described in the text including heme spin state in the substrate-free and substrate-bound 
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iron can then bind O2 (D). However, this complex is unstable and can lead to the 
formation of superoxide anion and ferric iron. A second electron is then transferred from 
reductase, or, in certain instances, it has also been shown that this electron can come from 
cytochrome b5. A proton is then added (E’), followed by cleavage of the O-O bond, 
generating H2O and the FeV=O complex. Activated oxygen is then inserted into the 
substrate and the product is released (F) [8]. 
 
P450 Redox Partners 
Figure 1.3 shows the electron transfer pathway from redox partners reductase and 
cytochrome b5. The reductase transfers two electrons derived from a hydride ion of 
NADPH via FAD and FMN to P450s in one-electron transfer steps. In the liver, P450s 
are present in large excess over reductase, with the ratios ranging from 10:1-20:1. Despite 
this ratio, P450s have been shown to form 1:1 complexes with reductase [11]. 
Metabolism studies can be carried out in vitro by reconstituting P450 and reductase in a 
1:1 or 1:2 ratio depending upon the P450 being utilized in the study [12, 13]. In certain 
instances, cytochrome b5 has been shown to donate the second electron to the P450. 
Cytochrome b5 is thought to be involved only in the transfer of the second electron, 
because it is very inefficient at delivering the first electron. This may be due to the fact 
that the second reduction is more thermodynamically favorable than the first [14]. 
Cytochrome b5 is a 17-kDa heme-containing protein that is located in the 
membrane of the endoplasmic reticulum [15], and it functions as an electron donor in a 
number of reactions, including cholesterol biosynthesis and certain P450-catalyzed 

































Figure 1.3 – Electron transfer pathways to the P450 in the endoplasmic reticulum 
[15]. In vivo, cytochrome b5 can receive an electron from NADH via cytochrome b5 
reductase. In the reconstituted system, the P450 is incubated with reductase and NADPH 
is the sole source of electrons. In the presence of cytochrome b5, the second electron in 
the catalytic cycle can be transferred from reductase to reduce cytochrome b5, then 







cytochrome b5 has been shown to increase, inhibit, or have no effect on P450 activity 
[17]. Studies on the effects of the b5 protein on P450 2B enzymes began in the early 
1980’s with the observation by Canova-Davis and Waskell that metabolism of 
methoxyflurane by P450 2B4 in the reconstituted system exhibited an absolute 
requirement for cytochrome b5 [18, 19]. Interestingly, cytochrome b5 had no effect on 
P450 2B4-mediated metabolism of benzphetamine [20]. There are two primary 
hypotheses to explain the stimulatory effect of cytochrome b5 on some P450-mediated 
reactions. The first is that reduced cytochrome b5 donates the second electron in the 
catalytic cycle to the P450 [21-23]. This is supported by studies showing electron transfer 
from cytochrome b5 to P450 as well as the observation that “uncoupling” is decreased in 
the presence of the b5 protein [24]. The second hypothesis is that cytochrome b5 
physically interacts with the P450 causing a conformational change that facilitates 
interaction with the substrate or reductase. This notion is supported by studies where the 
apo-cytochrome b5, which cannot be reduced and donate the second electron, was able to 
stimulate P450-catalyzed reactions [25]. However, the exact role of cytochrome b5 in 
P450-dependent hydroxylation and oxidations is unclear. Again, it appears that the effect 
is highly dependent upon the substrate and the isoforms being studied. 
 
Mechanism-Based Inactivation 
In the clinical setting, P450 inhibition can result in elevated plasma levels of other 
drugs that are primarily metabolized by the particular P450 being inhibited. As a result, 
inhibition of P450s has the potential to cause severe adverse events. For instance, studies 
with patients that are receiving warfarin along with 5-fluorouracil (a P450 inhibitor) to 
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treat a cancer have exhibited altered coagulation parameters, bleeding, and even death in 
some cases [26]. P450 inhibition may also result in decreased metabolism of prodrugs, 
such as cyclophosphamide, that have to be metabolically activated [27]. Alternatively, 
P450 inhibition can be used to increase the bioavailablity of a compound. For example, 
ritonavir, a potent inhibitor of P450 3A4 [28], has been co-formulated with lopinavir, a 
novel protease inhibitor with relatively low bioavailability [29]. The combined drug 
formulation was shown to significantly improve the pharmacokinetic properties and 
hence the activity of lopinavir against HIV-1 protease [30]. In vitro, P450 inhibition is a 
useful tool to help elucidate the relative contributions of particular P450s in the 
metabolism of a substrate. 
There are three steps in the P450 catalytic cycle that appear to be susceptible to 
inhibition: 1) substrate binding, 2) binding of molecular oxygen to the ferrous enzyme, 
and 3) transfer of activated oxygen from the heme iron to the substrate [31]. Inhibitors 
can then be divided into three categories based upon their mechanism of action: 1) 
reversible, 2) quasi-irreversible, and 3) irreversible. Reversible inhibition, or competitive 
inhibition, most often occurs when there is structural similarity between the inhibitor and 
the substrate(s) of the P450 [31]. The inhibitor itself may be a substrate for the P450; 
however, this is not necessarily required. Competitive inhibition is considered to be 
solely dependent upon concentration, as opposed to quasi-irreversible inhibition and 
irreversible inhibition, which are both time- and concentration-dependent. 
Quasi-irreversible inhibition occurs when a compound is metabolized to an 
intermediate that then binds tightly to the heme or the P450, resulting in inhibition of 
enzymatic activity. This phenomenon has been described for a variety of compounds, 
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including erythromycin where a metabolite intermediate (MI) complex is formed with the 
P450 heme iron, resulting in inhibition. The formation of this complex can be observed 
spectrally at a maximum absorbance of 455 nm [32-34]. Blobaum et al. [35, 36] have 
described a second type of reversible intermediate (maximum absorption at 485 nm) that 
can be observed during inactivation of P450 2E1 T303A by tert-butyl acetylene. 
Irreversible inhibition in which metabolism of the compound leads to covalent 
binding to the heme or protein, is also termed “mechanism-based inactivation”.  
Mechanism-based inactivation is defined as the process in which a substrate is 
metabolized and converted to a reactive intermediate that binds irreversibly to the active 
site of the P450, thereby rendering it inactive [37]. 
The criteria employed to identify a mechanism-based inactivator in vitro are as 
follows [38]: 
1) the inhibition is time-, concentration- and NADPH-dependent; 
2) addition of exogenous nucleophiles, such as glutathione, does not protect the 
enzyme from inactivation; 
3) the inactivation is irreversible, and the activity cannot be recovered after dialysis 
or gel filtration; 
4) the decrease in activity exhibits pseudo-first order kinetics; 
5) addition of a substrate with high affinity for the P450 can protect against 
inactivation; 
6) total P450 content is reduced; 
7) 1:1 stoichiometry is observed with complete inhibition of enzymatic activity. 
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Investigation of mechanism-based inactivators can lead to useful information for 
understanding the architecture of the P450 active site. Further, increased knowledge 
about mechanism-based inactivators has the potential to aid in the prevention of certain 
drug-drug interactions. 
 
Cytochromes P450 Polymorphisms 
Inter-individual variability in P450 activity is a major reason for failure of drug 
therapy [39]. Variability in P450 activity can be caused by a number of factors, including 
age, gender, morbidity and disease state, as well as concurrent medications, diet, alcohol 
and smoking. However, genetic polymorphisms appear to play the largest role in 
variability observed in patients [40]. Mutations have been found in all genes encoding 
P450 enzymes in families 1-3, although the functional importance of the variant alleles 
differs along with the frequencies of their distribution [41]. P450 activity for certain 
metabolic reactions has been shown to vary up to fifty-fold between individuals [42]. The 
wild-type alleles of P450s where genetic mutations have been found are denoted as “*1” 
and the allelic variants (containing one or more single nucleotide polymorphism(s)) are 
sequentially numbered as they are identified (i.e., *2, *3). Polymorphic P450s play a 
large role in adverse drug reactions. It has been estimated that 56% of drugs that are cited 
in adverse drug reaction studies are primarily metabolized by polymorphic phase I 
enzymes, of which 86% are P450s [43]. The costs associated with treating patients who 
express variant forms of P450s are significantly greater than those required to treat 
patients expressing wild-type P450s [44]. The majority of investigations into the effects 
of P450 polymorphisms are done by genotyping patients and correlating the genetic 
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differences to phenotypic differences. Ingelman-Sundberg has suggested that information 
gained from fundamental studies of the effects of P450 polymorphisms could result in a 
10-20% improvement of clinical efficacy of all drug therapy and a 10-15% reduction of 
the frequency of adverse drug reactions [41]. With this in mind, studies investigating the 
mechanisms behind phenotypic differences, which are currently lacking, are necessary to 
aid in safer and more efficacious drug development. 
 
Cytochromes P450 2B6 and P450 2B6 K262R 
P450 family 2 enzymes collectively catalyze over 54% of all phase I oxidations of 
drug substrates [45]. P450 2B6 is a polymorphic human P450 that is expressed in a 
variety of tissues including the liver, skin [46], kidney [47], heart [48], brain [49] and 
larynx [50]. P450 2B6 is involved in the metabolism of about 3% of clinically used drugs 
including sertraline, a selective serotonin reuptake inhibitor [51, 52]; cyclophosphamide, 
a prodrug that is an anticancer agent [27]; and propofol, an anesthetic [53, 54]. P450 2B6-
specific substrates include efavirenz, a non-nucleoside transcriptase inhibitor [55] and 
bupropion, an anti-depressant and smoking cessation aid [56, 57]. This enzyme has been 
shown to play a role in the activation of a number of procarcinogens, including aflatoxin 
and tobacco-specific nitrosamines [58, 59]. In addition, P450 2B6 can activate certain 
centrally active drugs, such as cocaine [60] and amphetamines [61], to neurotoxic 
intermediates. P450 2B expression is induced by a number of compounds, including 
phenobarbital and nicotine, which primarily increases P450 2B expression in the brain 
[62]. 
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 A number of single nucleotide polymorphisms have been found in the P450 2B6 
gene that encode variant alleles currently denoted as 2B6*2 through 2B6*25. In vivo 
studies have suggested that these variant alleles exhibit phenotypic differences when 
compared to the wild-type [63-65]. P450 2B6 polymorphisms have differential effects on 
the metabolism of P450 2B6 substrates. The P450 2B6 lysine 262 to arginine mutant 
[2B6*4 (2B6.4 when referring to the purified enzyme; K262R), 785A>G, exon 5] is of 
particular interest because it has been reported to have a 5-9% allele frequency and up to 
an overall 50% mutation frequency since it is present in multiple variant alleles [66-68]. 
In a clinical study, P450 2B6*4 was associated with an increased clearance of bupropion 
and higher plasma levels of the hydroxybupropion metabolite in German males [69]. 
Bupropion, a widely used anti-depressant and smoking cessation aid, acts by inhibiting 
the reuptake of norepinephrine and dopamine [70, 71]. P450 2B6 is the primary enzyme 
catalyzing the hydroxylation of bupropion to form hydroxybupropion, the 
pharmacologically active metabolite that plays a role in the antidepressant and, 
presumably, anti-smoking activity of bupropion [70]. Elevated plasma concentrations of 
hydroxybupropion are thought to be associated with seizures, the most severe side effect 
of bupropion treatment, occurring in 1 in 1000 patients [72]. Therefore, patients 
expressing this variant allele who take the standard therapeutic dose of bupropion to treat 
depression or nicotine addiction may have an increased risk of side effects. Since this 
mutation occurs with such a high frequency, a better understanding of the mechanisms of 
its effects are critical to understanding and predicting adverse drug reactions. 
The x-ray crystal structure of P450 2B6 has not yet been solved, however the 
structure of the rabbit isoform is available in both an open and closed confirmation [73, 
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74]. Since P450 2B4 and P450 2B6 are members of the same subfamily, the x-ray crystal 
structure of P450 2B4 can be used a model to help understand the architecture of P450 
2B6. The P450 2B4 structure reveals a large open cleft, approximately 15Å wide, 
between the α-helical and β-rich domains that extends directly to the heme and originates 
from the distal surface of the protein [73]. The cleft is composed of helices F, F’, G’ and 
G on one side and by the B’/C loop and the C helix on the opposite side. The C helix is 
on the proximal side of the protein and contains a strong electropositive potential that can 
interact with the negatively charged surface of redox partners, reductase and/or 
cytochrome b5. Mutation of residues R122 and F126 in helix C have been shown to effect 
association with both redox partners [75]. When the open structure of P450 2B4 is 
superimposed with the closed structure (Figure 1.4), one of the regions with the highest 
root mean square difference is the G/H loop, the site of residue K262. Substrate binding 
has been demonstrated to enhance redox partner binding and P450 2B4 reduction [76]. In 
the substrate bound structure of P450 2B4, portions of the G/H loop interact with residues 
in the C/D loop, which causes a 4Å shift when compared to the open conformation. This 
interaction significantly alters the orientation of helix C, suggesting that, when the 
substrate is bound, the G/H loop may provide a physical mechanism for conformational 
change that facilitates electron transfer from redox partners [74]. The G/H loop of the 
closed structure is relatively small consisting of only eight residues.  
With this in mind, it is reasonable to hypothesize that mutating lysine 262 in the 
G/H loop to an arginine, which is slightly larger, could result in altered interaction with 
redox partners. Further, since the interaction with redox partners is effected by substrates, 


















Figure 1.4 - Spatial relationships between the open P450 2B4 (blue) and closed P450 
2B4 (yellow) [74]. The G/H and C/D loops are regions with high root mean square 
differences between the two structures. The interaction of these loops with other areas of 
the protein and the flexibility of these loops facilitates the repositioning of the C helix, 
which is involved in redox partner binding. Residues shown by site-directed mutagenesis 







has been described where a lysine to arginine mutation of the estrogen receptor-α on the 
border of the hinge-region of the hormone binding domain affects the binding of co-
activators [77]. Strobel and colleagues have reported that mutating a lysine residue in the 
G/H loop of P450 1A1 altered the ability of the P450 to metabolize substrates in the 
presence of reductase [78]. In subsequent studies, the use of cumene hydroperoxide as an 
oxidant in a reductase-free system resulted in the ability of the mutant to metabolize the 
substrate similar to the wild-type enzyme, suggesting that the mutation interrupted 
electron-transfer [78]. The studies in this thesis were designed to test the functional 
consequence of the P450 2B6 K262R mutation in vitro on the catalytic activity of the 
enzyme, with a particular focus on mechanism-based inactivation. Because of the 
location of the mutation, the effects of the presence of cytochrome b5 have also been 
examined in order to test the hypothesis that the K262R mutation exhibits differences in 
catalytic activity as a result of altered interaction with redox partners when compared to 
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THE NATURALLY OCCURRING P450 2B6.4 MUTANT OF P450 2B6 EXHIBITS 




A number of single nucleotide polymorphisms (SNPs) have been found in the 
P450 2B6 gene [1]. However, the ability of these variants to metabolize other substrates 
and the response of these variants to known inactivators of P450 2B6 have not yet been 
examined. P450 2B6 K262R (2B6*4, 785A>G, exon 5; 2B6.4) is associated with 
increased clearance of bupropion and higher levels of the hydroxybupropion metabolite 
in German males [2].  This chapter details our investigations of the effects of this SNP on 
the metabolism of several P450 2B6 substrates including bupropion and the ability of 
P450 2B6.4 to become inactivated by three structurally unrelated mechanism-based 
inactivators of P450 2B6 (Figure 2.1).       
Bupropion is a widely used anti-depressant and smoking cessation aid that acts by 









Figure 2.1 - Chemical structures of the mechanism-based inactivators N,N’,N” 



















shown to be effective in the treatment of attention deficit/hyperactivity disorder (ADHD) 
in adults [5]. In humans, bupropion is extensively metabolized to give three primary 
metabolites: erythrohydrobupropion, threohydrobupropion, and hydroxybupropion 
(Figure 2.2) [6]. P450 2B6 catalyzes the hydroxylation of bupropion to form 
hydroxybupropion, which is the pharmacologically active metabolite that plays a role in 
the antidepressant activity of bupropion [3]. Side effects of bupropion include seizures 
and even death [7]. It has been reported that approximately 1 in 1000 subjects treated 
with bupropion experience seizures [8]. Elevated plasma level concentrations of 
hydroxybupropion are thought to be associated with poor clinical outcomes and seizures 
[7, 9, 10]. 
N, N’, N” -triethylenethiophosphoramide (tTEPA), bergamottin and 17-α-
ethynylestradiol (17EE) are all mechanism-based inactivators of  P450 2B6 in a 
reconstituted system with reductase [11-16].  Mechanism-based inactivation occurs when 
the enzyme converts the substrate to a reactive intermediate that binds covalently to a 
moiety in the active site and thereby inactivates the enzyme.  tTEPA is an anti-neoplastic 
agent used in the treatment of breast, bladder and ovarian cancers [17].  Bergamottin, a 
furanocoumarin found in grapefruit juice, inactivates P450s 3A4 [18], 2B6, and 3A5 [15]. 
17EE, a major component of many oral contraceptives is also a mechanism-based 
inactivator of P450 2B6 [12, 14].  Because these compounds all inactivate the wild-type 
form of P450 2B6, their use may be problematic in the clinic when given in combination 
with a drug that is primarily metabolized by this enzyme. The effects of these substrates 
and inactivators on the allelic variant P450 2B6.4 reported here show significant 




















































Materials.  Bupropion hydrochloride, triprolidine hydrochloride, NADPH, BSA, 
benzphetamine, catalase and 17EE were purchased from Sigma Chemical Co. (St. Louis, 
MO). tTEPA was purchased from U.S. Pharmacopeia (Rockville, MD) and bergamottin 
from Indofine Chemical Co. (Hillsborough, NJ). 7-Ethoxy-4-(trifluoromethyl)coumarin 
(7-EFC) was obtained from Molecular Probes (Eugene, OR). Hydroxybupropion was 
purchased from BD Biosciences (San Diego, CA). The P450 2B6 plasmid was a generous 
gift from Dr. James Halpert, University of Texas Medical Branch, Galveston, Texas. This 
P450 2B6 had amino acids 3-21 deleted and minor changes made to increase expression 
and solubility [19]. Purified benzphetamine and D-norbenzphetamine were a gift from 
Dr. Haoming Zhang, Department of Anesthesiology, Veteran Affairs Health Service, Ann 
Arbor, Michigan.  
 
Statistical analysis. Graphs and the two-tailed unpaired t-test were performed using 
GraphPad Prism version 3.00 for Windows (GraphPad Software, San Diego, California). 
Km and Vmax values were determined using EZ-Fit ™: Enzyme kinetic analysis (Perrella 
Scientific Inc., Amherst, NH). Data were fit using the Michaelis-Menten & unstable 
enzyme kinetics routine.   
 
Site-directed mutagenesis. Construction of the P450 2B6.4 mutant was performed with 
Stratagene’s Quik-Change site-directed mutagenesis kit (Stratagene, La Jolla, CA) using 
primers: 5’ GACCCCAGCGCCCCCAGGGACCTCATCGACACCTAC3’ (upstream) 
and 5’ GTAGGTGTCGATGAGGTCCCTGGGGGCGCTGGGTC3’ (downstream). The 
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mutation was confirmed by DNA sequencing carried out at the University of Michigan 
Core Facility (Ann Arbor, MI).  
Expression and purification of P450s and NADPH-cytochrome P450 Reductase 
(Reductase).  P450 2B6, P450 2B6.4 and NADPH-P450 reductase were expressed in E. 
coli Topp 3 cells and purified according to published protocols [19-21] except that  P450 
2B6.4 was recovered from the cytosol rather than the microsomal fraction after the cell 
lysis step.  Therefore, the cytosol was applied to the Ni++-agarose column and the P450 
was purified as previously described [19, 20]. 
 
Bupropion metabolism.  Purified P450s were reconstituted with reductase at a 1:2 ratio 
of P450 to reductase for 45 min at 4 °C. The reaction mixture consisted of 1 μM P450, 2 
μM reductase, 110 U catalase and bupropion (concentrations ranging from 0 μM to 960 
μM). NADPH was added to initiate the reactions and the mixtures were incubated for 30 
min at 37 °C.  The reaction was quenched by the addition of 125 μL of ice-cold 
acetonitrile containing 0.1% formic acid.  The samples were then placed on ice and 
centrifuged at maximum speed for 10 min in an Eppendorf microcentrifuge at 4 °C.  The 
method used to determine the concentration of hydroxybupropion was adapted from 
Faucette et al. [22].  Triprolidine (2 µl of a 20 mg/ml stock) was added as an internal 
standard and the samples were resolved on  a 5 μm Waters Symmetry 15 x 3.9-mm C18 
column (Millipore Corp., Milford, MA) at a flow rate of 1 ml/min, with the detector set at 
214 nm.  A gradient  was generated with mobile phases A (0.25% triethylamine and 0.1% 
formic acid) and B (100% acetonitrile) that ranged from 13% B at 0 to 15.5 min, 25% B 
at 16 to 23 min, and 13% B at 23.5 to 35 min.  The retention times were approximately 
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4.5 min for hydroxybupropion and 22 min for triprolidine. Hydroxybupropion formation 
was quantified from a standard curve generated by injecting increasing concentrations of 
authentic hydroxybupropion onto the HPLC column.    
 
Benzphetamine metabolism. The P450s were reconstituted as above and the formation 
of formaldehyde via N-demethylation of benzphetamine was measured as previously 
described [23]. A saturating concentration of benzphetamine (2mM) was added to all 
samples. The amount of formaldehyde formed was determined using an excitation 
wavelength of 410 nm and an emission wavelength of 510 nm using a RF-5310 
Spectrofluorophotometer (Shimadzu Scientific Instruments, Inc., Wood Dale, IL) and 
quantified from a standard curve. The individual metabolites of benzphetamine were also 
identified after adding the internal standard D-norbenzphetamine and after extraction of 
the metabolites with ethylacetate followed by separation and detection using ESI-LC-MS 
according to a previously published procedure [24].  Because this ESI-LC-MS analysis 
did not allow for precise quantitation of each metabolite, the area under the peak of the 
metabolite was integrated and used for comparison purposes only between the two 
enzymes. 
 
Inactivation of P450s 2B6 and 2B6.4.  The purified P450s were reconstituted with 
reductase for 45 min at 4 °C.  The primary reaction mixture contained 1 μM P450, 2 μM 
reductase, 110 U catalase and either tTEPA (100 µM), BG (10 µM) or 17EE (100 µM) in 
50 mM potassium phosphate buffer, pH 7.4.  The primary reaction mixtures were then 
incubated for 10 min at 30 °C prior to initiating the reactions by adding NADPH to a 
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final concentration of 1.2 mM.  After the addition of NADPH, 12 μL aliquots were 
removed from the primary reaction mixture at the times indicated and transferred to 990 
μL of the secondary reaction mixture which contained 100 μM 7-EFC, 1mM NADPH 
and 40 μg BSA/mL in 50 mM potassium phosphate buffer, pH 7.4.  The reaction 
mixtures were incubated for 10 min at 30 °C, and then quenched with 334 μL of 
acetonitrile. The amount of 7-hydroxy-4-(trifluoromethyl) coumarin formed was 
measured at room temperature at an excitation wavelength of 410 nm and an emission 
wavelength of 510 nm using a RF-5310 Spectrofluorophotometer (Shimadzu Scientific 
Instruments, Inc., Wood Dale, IL). The amount of hydroxybupropion formed was 
determined as indicated previously for bupropion metabolism. For the tTEPA kinetic 
experiments, the primary reaction mixtures contained tTEPA concentrations ranging from 
0 μM to 240 μM. The bergamottin kinetics experiments were performed using 
concentrations ranging from 0 μM to 12 μM. Aliquots (12 µL) were removed and added 
to the secondary reaction mixture at the indicated times.  
 
17EE metabolism. P450 2B6 or P450 2B6.4 were reconstituted together with reductase 
as described above.  The primary reaction mixtures contained 1 μM P450, 2 μM 
reductase, 200 μg/ml ascorbate, 110 U catalase, 40 μM 17EE and 50 mM potassium 
phosphate buffer, pH 7.4.  The metabolites were resolved by reverse-phase HPLC 







Hydroxybupropion formation by P450 2B6 and P450 2B6.4. Metabolism of the P450 
2B6 specific substrate bupropion to hydroxybupropion was examined using HPLC. 
Figure 2.3 shows the rate of formation of hydroxybupropion produced by P450 2B6 and 
P450 2B6.4 at substrate concentrations ranging from 0 µM-960 µM. Buproprion was 
poorly soluble at concentrations higher than 960 μM. The Km value for P450 2B6 was 
approximately 8.8 µM while the Km value for P450 2B6.4 was approximately 54 µM. The 
Vmax of the variant was approximately 6.9 nmol hydroxybupropion/nmol P450/min 
whereas the Vmax of the wild-type was 2.6 nmol hydroxybupropion/nmol P450/min. The 
Vmax/ Km for P450 2B6 was approximately 0.30 while the Vmax/ Km for P450 2B6.4 was 
approximately 0.13.  Therefore, the catalytic efficiency (Vmax/ Km) of the variant for 
buproprion was approximately 40% less than that of the wild-type enzyme.  
 
Benzphetamine metabolism by P450 2B6 and P450 2B6.4. The enzymatic activities of 
P450 2B6 and P450 2B6.4 were compared using benzphetamine as a substrate. The 
ability of each enzyme to metabolize benzphetamine to formaldehyde was determined 
first. P450 2B6.4 N-demethylated benzphetamine to produce 9.4 ± 0.9 pmol 
formaldehyde/pmol P450/min while the wild-type P450 2B6 generated 16.3 ± 1.3 pmols 
formaldehyde/pmol P450/min (Figure 2.4). The individual metabolites norbenzphetamine 
(N-demethylation), amphetamine (N-demethylation and N-debenzylation), 
methamphetamine (N-debenzylation), hydroxynorbenzphetamine (N-demethylation and 
aromatic hydroxylation) and hydroxybenzphetamine (aromatic hydroxylation) were also 

















Figure 2.3 - Metabolism of bupropion to hydroxybupropion by P450 2B6 and P450 
2B6.4. Samples were reconstituted as described in Experimental Procedures and 
incubated with bupropion ranging from 0 μM to 960 μM.  Hydroxybupropion formation 
by P450 2B6.4 ( ) and P450 2B6 ( ) was measured by integrating the area under the 
HPLC peak and comparison to areas from a standard curve generated by injecting 
different amounts of authentic hydroxybupropion on the HPLC column. The data 

























Figure 2.4 - Metabolism of benzphetamine by P450 2B6 and P450 2B6.4. N-
demethylation of benzphetamine to formaldehyde was measured as described in the 















Table 2.1 - Metabolism of benzphetamine by P450s 2B6 and 2B6.4. P450s were 
reconstituted in the presence of reductase as described in Experimental Procedures. A 
saturating concentration of benzphetamine was used and samples were incubated for 30 
min at 30°C.  Metabolites were isolated and analyzed by ESI-LC-MS.  Standard error of 
the mean (SEM) is shown.  
 
 
                                                   2B6                       2B6.4                          2B6/2B6.4 
Area under the peak 
Norbenzphetamine 13 ± 0.13 7.6 ± 0.12 1.7 
Amphetamine 0.17 ± 0.01 .06 ± 0.001 2.9 
Methamphetamine N.D.1 N.D. - 
OH-norbenzphetamine 5.8 ± 0.03 1.0 ± 0.02 5.8 








It can be seen that the mutation caused a decrease of approximately 50% or greater in the 
formation of most of the metabolites except for OH-norbenzphetamine, where it’s 
formation by the mutant was less than 20% of that formed by the wild-type enzyme. 
 
Inactivation of P450s 2B6 and 2B6.4 by tTEPA, bergamottin and 17EE. The 
inactivation of P450 2B6.4 by these three mechanism-based inactivators was performed 
as described in the Experimental Methods. P450 2B6.4 was inactivated by both tTEPA 
(Figure 2.5) and bergamottin (Figure 2.6). The inactivation  was time- and concentration-
dependent with both compounds and displayed an absolute requirement for NADPH. The 
approximate KI value for the tTEPA-mediated inactivation of the variant determined from 
the inset of Figure 4 was 210 µM with a t1/2 of 18.6 min and a rate of inactivation of 0.04 
min-1 as measured using the 7-EFC O-deethylation assay. The approximate KI value for 
the inactivation of P450 2B6.4 by bergamottin determined from the inset of Figure 5 was 
8.2 µM, the rate of inactivation was 0.23 min-1 with a t1/2 of 3.01 min as determined using 
the 7-EFC O-deethylation activity assay. 17EE has previously been shown to be a 
mechanism-based inactivator of the P450 2B6 wild-type enzyme [14]. In contrast to the 
wild-type enzyme, 17EE had no effect on the 7-EFC activity of the P450 2B6.4 mutant. 
In order to see if the loss in enzymatic activity observed with 7-EFC was substrate-
dependent, each of the samples incubated with the three inactivators and NADPH was 
also analyzed simultaneously using the bupropion hydroxylation assay (Table 2.2). 
Bergamottin had the greatest effect on both P450 2B6 and P450 2B6.4 leaving 

















Figure 2.5 - Inactivation of P450 2B6.4 by tTEPA. The time- and concentration-
dependent inactivation of P450 2B6.4 was measured by determining the 7-EFC O-
deethylation activity. After initiation of inactivation by the addition of NADPH, aliquots 
were removed from the primary reaction mixture at 0, 5, 10, 16 and 21 min. The 
concentrations of tTEPA were ( ) 0 μM, ( ) 80 μM, ( ) 120 μM, ( ) 160 μM, ( ) 
200 μM and ( ) 240 μM.  The data show the means and standard deviations from 4 
separate experiments using duplicate samples.  The inset represents the double reciprocal 

















Figure 2.6 - Inactivation of P450 2B6.4 by bergamottin. The time- and concentration-
dependent inactivation of P450 2B6.4 was measured by determining the 7-EFC O-
deethylation activity. After the addition of NADPH, aliquots were removed from the 
primary reaction mixture at 0, 2, 4, 6, and 8 min. The concentrations of bergamottin were 
( ) 0 μM, ( ) 1 μM, ( ) 2 μM, ( ) 4 μM, ( ) 8 μM, and ( ) 12 μM. The data show 
the means and standard deviations from 3 separate experiments using duplicate samples. 
The inset depicts the double reciprocal plot of the rates of inactivation as a function of the 








Table 2.2 - Effect of bergamottin, tTEPA, and 17EE on the bupropion 
hydroxylation and 7-EFC activities of P450s 2B6 and 2B6.4. P450s 2B6 and 2B6.4 
were reconstituted with reductase as described in Experimental Procedures. Bergamottin, 
tTEPA and 17EE were present in the primary reaction mixture at concentrations of 10 
μM, 100 μM, and 100 μM, respectively.  NADPH was added to the primary reaction 




Percentage of control activity remaining 
 
 Bupropion assay 7-EFC assay 
 
2B6 Bergamottin 30 ± 1 34 ± 2 
2B6.4 Bergamottin 31 ± 1 40 ± 3 
 
2B6 tTEPA 51 ± 2 55 ± 3 
2B6.4 tTEPA 62 ± 3 81 ± 4 
 
2B6 17EE 61 ± 4 23 ± 3 




and similar effects were seen using both assays. tTEPA inactivated the wild-type enzyme 
to a greater extent than the variant. There was a very significant difference between the 
inactivation of the mutant enzyme by tTEPA as determined by the bupropion assay when 
compared to the 7-EFC assay (p=.0028), although no significant difference was seen with 
the wild-type enzyme. 17EE inactivated the wild-type P450 2B6 leaving 61% activity 
remaining with bupropion as the probe substrate  while the P450 2B6.4 was not 
inactivated at all by 17EE. There was also a significant difference between the 
inactivation of the wild-type enzyme by 17EE when measured by the bupropion assay as 
compared to the 7-EFC assay (p=.0002). 
 
Metabolism of 17EE by P450s 2B6 and 2B6.4. In order to see if the lack of inactivation 
of 2B6.4 by 17EE was due to an inability of the enzyme to catalyze the metabolism of 
17EE, the metabolism of 17EE by the two P450s was investigated. 17EE was incubated 
with the reconstituted P450s in the presence or absence of NADPH and the metabolites 
analyzed using reverse phase HPLC as shown in Figure 2.7. P450 2B6 metabolized 17EE 
to give a number of major metabolites denoted as A, C, D and E as well as numerous 
other minor metabolites as previously described [14] (Panel A). However, as shown in 
Panel B, P450 2B6.4 did not produce any metabolite of 17EE above the levels of the 
control incubations incubated in the absence of NADPH.  
 
Discussion 
 These studies comparing the metabolic activities of purified P450 2B6 and P450 























Figure 2.7 - Metabolism of 17EE by P450s 2B6 and 2B6.4. Samples were reconstituted 
and incubated with 17EE in the presence or absence of NADPH as described in 
Experimental Procedures. The metabolites of 17EE produced by P450 2B6 (Panel A) and 
P450 2B6.4 (Panel B) were separated as described in Experimental Procedures. The 
identities of metabolites labeled  A1, A2, and C have not yet been determined.  Metabolite 
D corresponds to 2-hydroxy-17EE, metabolite E corresponds to estrone and F 
corresponds to the substrate, 17EE [14]. 
D
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K262R variant results in a dramatically different ability of the mutant to metabolize a 
number of P450 2B6 specific drugs compared to the wild-type enzyme. Though regarded 
as a relatively minor component of the P450 family in the liver, P450 2B6 has been 
shown to play a significant role in the metabolism of many xenobiotics and in the 
activation of a number of pro-carcinogens including 4-(methylnitrosamino)-1-(3-
pyridyl)-1-butanone (NNK) [25-27]. A number of chemotherapeutic drugs such as 
tTEPA are substrates for 2B6 and they are often given in combination with other drugs 
[13, 16, 17]. As a result, there is a significant potential for interactions with other drugs 
that are also metabolized by this enzyme (particularly in instances where this isoform is 
induced by other xenobiotics). Because P450 2B6 is polymorphic, drug interactions may 
be more detrimental for certain patients than for others, depending on the genotype. P450 
2B6 has previously been shown to be responsible for the interindividual variability of 
propofol hydroxylation in liver microsomes [28]. A recent study demonstrated higher 
mean plasma concentrations of efavirenz in patients homozygous for P450 2B6*6 
(Q172H, K262R) when compared to wild-type [29]. The K262R SNP is thought to be 
particularly important as it was found to have an allele frequency of approximately 5% in 
German males and a SNP frequency of 30%  since it is present in three different P450 
2B6 allelic variants (2B6*4, 2B6*6 and 2B6*7) [1, 2]. 
The studies presented here have focused on the potential effect of the K262R 
mutation in substrate metabolism and inactivation of this mutant in a reconstituted system 
by drugs that have been well characterized with the wild-type enzyme. Bupropion, a drug 
that is widely used to treat depression and aid in smoking cessation, is hydroxylated 
primarily by cytochrome P450 2B6 [22, 30]. Our findings suggest that P450 2B6.4 
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produced the hydroxylated product at a rate that was significantly greater than the wild-
type enzyme. The Km of wild-type P450 2B6 for bupropion in this study is one-tenth that 
previously reported in human liver microsomes [30]. This observation may be due to the 
differences in the protein or lipid composition between the reconstituted system 
employed in these studies and liver microsomes. It was not possible to use lower 
concentrations of bupropion in the kinetics studies because the amount of 
hydroxybupropion produced from lower bupropion concentrations was below the limits 
of detection of our assay. Because of the variability in expression of wild type P450 2B6 
or that of the naturally occurring mutant, it is difficult to extrapolate our in vitro data 
directly and to draw clinical implications. However, our results with bupropion are 
consistent with the findings in a population of German males, where subjects expressing 
the P450 2B6*4 allele displayed higher levels of hydroxybupropion as well as moderately 
increased clearance of bupropion [2]. 
Benzphetamine was readily metabolized by both P450 2B6 and P450 2B6.4 with 
the wild type enzyme generating approximately twice the amount of formaldehyde seen 
with the mutant.  When individual metabolites of benzphetamine were analyzed by ESI-
LC-MS, norbenzphetamine was found to be the primary metabolite produced by both 
enzymes, however the wild-type enzyme produced norbenzphetamine at levels 
approximately 1.7-fold greater than what was observed with P450 2B6.4. This 
observation is consistent with what was found using the formaldehyde assay, because 
norbenzphetamine is generated via N-demethylation with the release of formaldehyde, 
suggesting that N-demethylation is the primary route of metabolism of benzphetamine by 
the mutant as well. Amphetamine, which is the result of N-demethylation and N-
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debenzylation, was formed in small quantities by the mutant and wild-type. However, the 
wild-type enzyme produced amphetamine at a rate that was 2.9-fold greater than the 
variant. Interestingly, neither P450 2B6 or P450 2B6.4 metabolized benzphetamine to 
methamphetamine in the reconstituted system. This result, along with the low amounts of 
amphetamine produced, suggests that the N-debenzylation pathway is compromised in 
both of these enzymes. This is not due to truncation, as the full-length P450 also did not 
metabolize benzphetamine to methamphetamine (data not shown). In contrast, rat enzyme 
P450 2B1, produces significant amounts of methamphetamine and amphetamine [24]. 
These results demonstrate that there is a marked difference in specificity between the 
human and rat enzyme and that previous data obtained with the rat isofom may not be 
applicable for the human enzyme. P450 2B6.4 also preferentially metabolized 
benzphetamine via N-demethylation rather than aromatic hydroxylation. 
Hydroxynorbenzphetamine formed as a result of both N-demethylation and aromatic 
hydroxylation was produced at higher levels than hydroxybenzphetamine, which is 
generated solely by aromatic hydroxylation.  
The decrease in the ability of both enzymes to catalyze bupropion hydroxylation 
as well as 7-EFC O-deethylation when inactivated by tTEPA is shown in Table 2. This 
finding is consistent with a recent study that demonstrated that tTEPA inhibits bupropion 
hydroxylation in human liver microsomes [31]. The estimated KI value for the 
inactivation of P450 2B6.4 by tTEPA as measured using the 7-EFC activity assay was 
approximately 4-fold greater than the value previously reported for full-length P450 2B6 
[13]. The rate of inactivation of the mutant was approximately 3-fold less than what has 
been reported for the full-length wild-type enzyme [13]. tTEPA inactivated the variant 
 44 
 
and reduced hydroxylation of bupropion by 40% and O-deethylation of  7-EFC  by  20% 
at 100 µM. The estimated KI value for the bergamottin-mediated inactivation of P450 
2B6.4 and the rate of inactivation were approximately 2-fold greater and 3-fold greater, 
respectively, than what was observed with the wild-type enzyme [15], but the KI value of 
the mutant is similar to the value previously determined for P450 3A4 of 7.7 µM [18]. 
17EE is metabolized by P450 2B6 to give several metabolites and has been shown to be a 
mechanism-based inactivator for 2B enzymes [14]. Surprisingly, in contrast to other 
inactivators or the wild type enzyme, P450 2B6.4 was not inactivated by 17EE when 
incubated under identical conditions. Our inability to observe metabolites of 17EE 
suggests that the binding of this particular substrate to the mutated protein may be 
compromised by the mutation. The single mutation may have resulted in a significant 
structural alteration of the enzyme as may be suspected from the observation that this 
mutant was localized in the bacterial cytosol in contrast to the wild type enzyme of P450 
2B6 which is membrane-bound.  
Significant differences in the levels of inactivation were observed for both the 
wild-type P450 2B6 and the P450 2B6.4 mutant when different probe substrates were 
used to determine catalytic activity remaining. For example, P450 2B6 was inactivated to 
~80% when activity was measured using the 7-EFC O-deethylation assay whereas only 
40% inactivation was observed using the bupropion hydroxylation assay. P450 2B6.4 
was inactivated ~40% by tTEPA as determined using the 7-EFC assay but only ~20% 
based on the bupropion assay. Thus, the levels of inactivation differed not only between 
the wild-type and mutant enzymes, but also depended significantly on the substrate that 
was used to assay activity remaining. The differences in the levels of inactivation when 
 45 
 
the same protein is assayed using different substrates may be due to the fact that the 
covalently bound inactivator in the active site interferes more with the binding of one 
substrate than with the binding of another.  This may be due to differences in the sizes of 
the substrates, their binding orientations in the active site, or the presence of multiple 
potential binding regions in the active site having preferred binding for different 
substrates.  The differences observed between wild-type and mutant enzyme may be due 
to differences in the active site architectures of the two proteins.  It is of interest that 
bergamottin and tTEPA have greater effects on bupropion metabolism whereas 17EE 
exhibited a greater effect on 7-EFC metabolism.  
 In this study we have shown that P450 2B6.4 in the reconstituted system 
metabolized bupropion to hydroxybupropion at a faster rate than P450 2B6. The P450 
2B6.4 mutant was inactivated by tTEPA and bergamottin similarly to the wild type 
enzyme. In contrast, 17EE was not metabolized by the mutant under identical conditions 
and did not inactivate it. Our studies with this single P450 2B6 variant underscore the 
importance of investigating the functional consequences of genetic polymorphisms at the 
level of the proteins in order to be able to predict the potential consequences to the 
patient.  The results of these types of functional studies are of critical importance for the 
development of a comprehensive database for predictive genotyping in the clinic that 
could be used to increase the efficacy of some treatment regimens and decrease the extent 
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METABOLISM OF EFAVIRENZ AND 8-HYDROXYEFAVIRENZ BY P450 2B6 




 Efavirenz is a non-nucleoside reverse transcriptase inhibitor used in the treatment 
of human immunodeficiency virus-1 (HIV-1). Efavirenz is prescribed as part of a 
combination therapy and is particularly effective due to its long half-life of 40-55 hours 
following multiple doses [1].  P450 2B6 has been shown to be primarily responsible for 
the hydroxylation of efavirenz to 8-hydroxyefavirenz and 8,14-hydroxyefavirenz (Figure 
3.1) [2]. In vivo and in vitro studies have shown that 8-hydroxyefavirenz is formed 
rapidly and is the major metabolite formed [2, 3]. Polymorphisms of P450 2B6 may have 
a significant effect on efavirenz metabolism since it has been shown that patients 
genotyped as P450 2B6 *6/*6 (Q172H and K262R) have significantly higher mean 
plasma efavirenz concentrations than patients that are *6 heterozygous or that do not 
have *6 alleles [4]. Efavirenz has also been shown to inhibit bupropion hydroxylation in 
human liver microsomes [5].    
 In this study, we used recombinant N-terminally truncated P450 2B6 and P450 
2B6.4 to 1) evaluate the effect of the K262R mutation on the hydroxylation of efavirenz 















Figure 3.1 - Chemical structures of efavirenz and the two primary metabolites 

































enzymes, and 3) to investigate the ability of 8-hydroxyefavirenz , a major metabolite of 
efavirenz, to act as a mechanism-based inactivator of both enzymes.  We found that the 
mutant was able to metabolize efavirenz to 8- hydroxyefavirenz. In addition, efavirenz 
inactivated the wild-type 2B6 but not the mutant and the inactivation of 2B6 was 
reversible after dialysis.  In contrast to the results observed with the parent compound, 
incubations with the 8-hydroxy metabolite resulted in the irreversible inactivation of both 
enzymes. These studies provide valuable information regarding the effect of the K262R 
mutation on P450 2B6 catalytic activity.  In addition, these results show that 
hydroxylation of a substrate can lead to marked differences in the mechanism of 
inactivation.  These studies also suggest that efavirenz and 8-hydroxyefavirenz may be 
useful tools for studying the structure of the active site of P450 2B6. 
 
Experimental Procedures 
Materials.  Efavirenz was purchased from Toronto Research Chemicals (Ontario, 
Canada). 8-hydroxyefavirenz was a generous gift from Bristol-Myers Squibb. Bupropion 
hydrochloride, triprolidine hydrochloride, NADPH, BSA and catalase were purchased 
from Sigma Chemical Co. (St. Louis, MO). 7-Ethoxy-4-(trifluoromethyl)coumarin (7-
EFC) was obtained from Molecular Probes (Eugene, OR).  Barium hydroxide, 3-
aminophenol and hydroxylamine hydrochloride were purchased from Aldrich Chemical 
Co. (Milwaukee, WI). The P450 2B6 plasmid was a generous gift from Dr. James 
Halpert, University of Texas Medical Branch, Galveston, Texas. All other chemicals 
were of the highest grade commercially available.    
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Statistical analysis. Statistical analysis was performed using GraphPad Prism version 
3.00 for Windows (GraphPad Software, San Diego, California).   
 
Site-directed mutagenesis, expression and purification of P450s and NADPH-
cytochrome P450 Reductase (reductase).  Construction of the P450 2B6.4 mutant was 
performed as described previously [6]. P450 2B6, P450 2B6.4 and NADPH-P450 
reductase were expressed in E. coli Topp 3 cells and purified as previously described [7-
9] except that  P450 2B6.4 was recovered from the cytosol rather than the membrane 
pellet after the cell lysis step.  Therefore, the cytosol was applied to the Ni++-agarose 
column and the P450 was then eluted and purified as previously described. 
 
Efavirenz metabolism.  The method used to determine efavirenz metabolism was 
adapted from Ward et al.[2]. The purified P450s were reconstituted with reductase at a 
ratio of 1:2 of P450 to reductase for 45 minutes at 4 °C. The reaction mixtures consisted 
of 1 μM P450, 2 μM reductase, 110 U catalase and efavirenz (concentrations ranging 
from 0 μM to 60 μM). NADPH was added to initiate the reactions and the mixtures were 
incubated for 30 min at 37 °C.  The reactions were quenched by adding 500 μL of ice-
cold acetonitrile containing 0.1% formic acid.  The samples were then placed on ice and 
centrifuged at maximum speed for 10 min in an Eppendorf microcentrifuge at 4 °C.  The 
supernatants were placed in clean tubes and 500 µL of 0.5M NaOH, pH 10, was added.  
Testosterone (2 µL of a 20 µM stock) was added as an internal standard. The samples 
were extracted twice with ethyl acetate and dried under a stream of nitrogen. 200 μL of 
mobile phase was added and the samples were resolved on a Varian Microsorb-MV 250 x 
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4.6-mm C18 column (Varian Inc., Palo Alto, CA) at a flow rate of 0.8 ml/min with the 
detector set at 247 nm.  Isocratic conditions were used consisting of 55% mobile phase A 
(water, 0.1% trifluoroaceticacid) and 45 % mobile phase B (acetonitrile, 0.1% 
trifluoroaceticacid).  The retention times were approximately 13 min for the internal 
standard testosterone, 23.5 min for 8-hydroxyefavirenz, and 42 min for efavirenz.     
 
Inactivation of P450s 2B6 and 2B6.4.  The purified P450s were reconstituted with 
reductase for 45 minutes at 4 °C. The primary reaction mixtures contained 1 μM P450, 2 
μM reductase, 110 U catalase and efavirenz (0-50 µM) or 8-hydroxyefavirenz (0-120 
µM) in 50 mM potassium phosphate buffer, pH 7.4. The primary reaction mixtures were 
then incubated for 10 min at 30 °C prior to initiating the reactions by adding NADPH to a 
final concentration of 1.2 mM.  After the addition of NADPH, 12 μL aliquots were 
removed from the primary reaction mixtures at the times indicated and transferred to 990 
μL of the secondary reaction mixtures which contained 100 μM 7-EFC, 1 mM NADPH, 
and 40 μg BSA/mL in 50 mM potassium phosphate buffer, pH 7.4.  The secondary 
reaction mixtures were incubated for 10 min at 30 °C, and then quenched by the addition 
of 334 μL of acetonitrile. The amount of 7-hydroxy-4-(trifluoromethyl) coumarin formed 
was measured at room temperature using an excitation wavelength of 410 nm and an 
emission wavelength of 510 nm using a RF-5310 Spectrofluorophotometer (Shimadzu 
Scientific Instruments, Inc., Wood Dale, IL). The amount of 8-hydroxybupropion formed 
was determined as previously described [6]. To measure the effect of efavirenz on the 
cyclophosphamide (CPA) hydroxylation activity of the P450s, the primary reaction 
mixtures were incubated with 20 μM efavirenz at 37°C. After the addition of NADPH, 
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aliquots were removed at the times indicated. The secondary reaction mixtures contained 
100 µM CPA, 1 mM NADPH, and 40 µg BSA/mL in 50 mM potassium phosphate 
buffer, pH 7.4. CPA hydroxylation was determined using the procedure of Roy et al. 
[10].  
 
Reversibility of inactivation of P450s 2B6 and 2B6.4 by efavirenz. P450s were 
reconstituted and incubated with 50 µM efavirenz or 20 µM 8-hydroxyefavirenz (80 µM 
for P450 2B6.4) in the presence or absence of NADPH as described above. Aliquots were 
removed at 0 and 20 minutes to determine the amount of 7-EFC O-deethylation activity 
remaining as described above. Each sample was further analyzed for P450 remaining 
using the reduced CO spectral assay and intact heme by HPLC as described by Harleton 
et al. [11]. The remainder of each of the control and inactivated samples was dialyzed 
separately for 24 hours at 4°C in Slide-A-Lyzer cassettes (Pierce Chemical, Rockford, IL) 
against 2 x 500 mL dialysis buffer (50 mM potassium phosphate buffer, pH 7.4, 
containing 20% glycerol and 100 µM EDTA).  After dialysis, the samples were incubated 
with or without fresh reductase at 4°C for 15 minutes and catalytic activity, heme and 
reduced CO spectra analysis were again carried out as described above. 
 
Determination of spectral intermediate formation. P450s were reconstituted as 
described above and incubated with 10 µM efavirenz at 30°C for 10 min.  NADPH (0.6 
mM) was added to the sample cuvette and an equal amount of water was added to the 
reference cuvette.  Difference spectra were recorded from 350 to 700 nm using a DW2 
UV-Vis spectrophotometer (SLM Aminco, Urbana, IL) that was equipped with an OLIS 
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spectroscopy operating system (On-Line Instrument Systems, Inc., Bogart, GA). Scans 
were taken continuously at 2 minute intervals. 
 
Results 
Formation of 8-hydroxyefavirenz by P450 2B6 and P450 2B6.4. The metabolism of 
efavirenz to 8-hydroxyefavirenz by 2B6 and 2B6.4 was measured by HPLC. The rates of 
formation of 8-hydroxyefavirenz by P450 2B6 and P450 2B6.4 using concentrations of 
efavirenz ranging from 0 µM to 100 µM are shown in Figure 3.2. The kinetic constants 
for these reactions are shown in Table 3.1.  The approximate Km value for wild-type P450 
2B6 (14.3 µM) was very similar to the approximate Km for the variant (15.9 µM). The 
Vmax for 8-hydroxyefavirenz formation by P450 2B6 was approximately 4.3 pmol 
formed/pmol P450/min, whereas the Vmax of P450 2B6.4 was approximately 2-fold 
higher (8.1 nmol formed/nmol P450/min). The catalytic efficiency (Vmax/Km) of P450 
2B6.4 was approximately 66% greater than that of P450 2B6 (approximately 0.3 for 2B6 
as compared to approximately 0.5 for the mutant). 
 
Inactivation of P450 2B6 by efavirenz.  Inactivation of the wild-type enzyme was 
measured using the 7-EFC O-deethylation assay. The wild-type enzyme was inactivated 
by efavirenz (Figure 3.3) in a time- and concentration-dependent manner and the 
inactivation exhibited an absolute requirement for NADPH.  The activity loss followed 
pseudo first order kinetics. Linear regression analysis was performed and the kinetic 
constants for the efavirenz- mediated inactivation of the wild-type enzyme were 

















Figure 3.2 - Metabolism of efavirenz to 8-hydroxyefavirenz by P450 2B6 and P450 
2B6.4. Samples were reconstituted as described in Methods and incubated with efavirenz 
at concentrations ranging from 0 μM to 100 μM.  8-Hydroxyefavirenz formation by P450 
2B6 ( ) and P450 2B6.4 ( ) was measured by HPLC by integrating the area under the 
metabolite peak and comparing it to a standard curve generated by injecting known 
amounts of authentic 8-hydroxyefavirenz onto the HPLC. The data shown are 








































Table 3.1 - Kinetic constants for the formation of 8-hydroxyefavirenz by 
recombinant P450 2B6 and P450 2B6.4. Kinetic constants were determined from the 
data shown in Figure 3.2 as described in Experimental Procedures. 
 
Enzyme  
Kinetic Constant    P450 2B6             P450 2B6.4 
 
Km (μM) 14.3 15.9 
Vmax (pmol/pmol P450/min) 4.3 7.9 






























Figure 3.3 - Inactivation of P450 2B6 by efavirenz. The time- and concentration-
dependent inactivation of P450 2B6 was measured by determining the 7-EFC O-
deethylation activity as described in Methods. After initiation of inactivation by the 
addition of NADPH, aliquots were removed from the primary reaction mixture at 0, 5, 
10, 15 and 20 min. The concentrations of efavirenz were ( ) 0 μM, ( ) 5 μM, ( ) 10 
μM, ( ) 20 μM, ( ) 40 μM and ( ) 50 μM.  The data show the means and standard 
deviations from 4 separate experiments done in duplicate. In some cases the standard 
deviations were less than the size of the symbols. The inset shows the double reciprocal 
plot of the rates of inactivation as a function of the efavirenz concentrations. 






































was 0.04 min-1 giving a t1/2 of 16 min.  In contrast to the wild-type enzyme, the variant 
form of 2B6 was not inactivated by efavirenz at concentrations up to 200 μM as 
measured by the 7-EFC O-deethylation activity of the variant enzyme (data not shown). 
The effect of mechanism-based inactivation by efavirenz on the metabolism of other  
structurally unrelated P450 2B6 substrates was also determined to investigate the 
possibility that the inactivation of wild-type 2B6 and the observed lack of inactivation of 
the variant might be due to the 7-EFC substrate that was chosen to measure activity. P450 
2B6 samples that had been pre-incubated with efavirenz and NADPH were assayed for 
bupropion and cyclophosphamide hydroxylation activities (Table 3.2). Pre-incubation 
with efavirenz decreased the ability of the wild type P450 2B6 to hydroxylate both 
substrates. Approximately 45% of the initial bupropion hydroxylation activity and 42% 
of the CPA activity remained following incubation with 20 μM efavirenz. These values 
were similar to the activity remaining when 7-EFC was used as the substrate (Figure 3.2, 
and data not shown). As seen with 7-EFC, pre-incubation of the variant enzyme with 
efavirenz did not result in inactivation as measured by the hydroxylation of bupropion or 
CPA (data not shown). 
 
Reversibility of efavirenz-mediated inactivation of P450 2B6. As shown in Table 3.3, 
the inactivation of P450 2B6 by efavirenz was reversible after overnight dialysis and the 
enzymatic activity, reduced CO spectra and heme remaining were completely restored. 
Control and efavirenz inactivated samples were analyzed for activity, CO spectral and 










Table 3.2 - Effect of pre-incubation with efavirenz on the bupropion and 
cyclosphosphamide hydroxylation activities of P450 2B6. The P450s were 
reconstituted with reductase as described under Experimental Procedures. The primary 
reaction mixture contained the concentrations of efavirenz indicated.  NADPH was added 
to the primary reaction mixture to initiate the reaction. 
 
Percentage of Control Activity Remaining  
Primary Reaction Conditions              Bupropion                 Cyclophosphamide 
 
-NADPH + 10 μM Efavirenz 100 100 
+NADPH + 10 μM Efavirenz 62 ± 3 67 ± 5 
-NADPH + 20 μM Efavirenz 100 100 








Table 3.3 - Effect of efavirenz on P450 2B6 catalytic activity, P450 content as 
measured by the reduced CO spectrum and heme, before and after 24 hr dialysis.  
The assays were performed as described under Experimental Procedures. Samples were 
incubated for 15 min in the presence or absence of NADPH and the data are represented 
as percentages of the control samples incubated in the absence of efavirenz.  Samples 
were then dialyzed for 24 hrs.  The data represent the means and standard deviations of 3 
separate experiments. 
 
Percentage of Control  
Primary Reaction Conditions   Activity                    Reduced CO          HPLC 
Remaining                 Remaining              Heme 
 
Before dialysis                               
-Efavirenz + NADPH 100 100 100 
+Efavirenz + NADPH 32 ± 3 35 ± 4 31 ± 2 
After dialysis    
-Efavirenz + NADPH 100 100 100 
+Efavirenz + NADPH 98 ± 5 96 ± 4 101 ± 3 
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dialysis there was a 68% loss in activity, a 65% CO spectral loss and 69% heme loss.  
After dialysis for 24 hours, catalytic activity, reduced CO spectrum and the heme 
remaining had all returned to levels commensurate with the control samples. To 
determine if the reversibility observed was the result of MI complex formation, as has 
been observed with other reversible inactivators [12], difference spectra for efavirenz- 
inactivated versus control samples were determined. As shown in Figure 3.4, there is a 
peak with a maximum absorbance at 435 nm in the difference spectrum. This peak does 
not appear to be representative of a MI complex since MI complexes normally exhibit a 
characteristic peak absorbance at 455 nm, not at 435 nm. The addition of ferricyanide 
results in the loss of the peak that we observe at 435 nm suggesting that it is an 
intermediate. Additionally, this peak is not observed in the absence of NADPH. 
 
Inactivation of P450 2B6 and P450 2B6.4 by 8-hydroxyefavirenz. The ability of 8-
hydroxyefavirenz, the primary metabolite of efavirenz, to inactivate the wild-type and 
variant enzymes was also investigated.  Interestingly, inactivation by 8-hydroxyefavirenz 
was markedly different from the inactivation by the parent. Incubation of both enzymes 
with 8-hydroxyefavirenz led to inactivation in time-, concentration-, and NADPH-
dependent manners. The approximate KI value for the inactivation of 2B6 by 8-
hydroxyefavirenz was 6.4 µM, with a t1/2 of 11 min, and a rate of inactivation of 0.06 
min-1, as measured by 7-EFC O-deethylation activity remaining Figure 3.5.  In contrast to 
what had been observed with efavirenz, the P450 2B6 variant was also inactivated by 8-
hydroxyefavirenz although the estimated KI was approximately 10-fold higher than for 







Figure 3.4 - Formation of a spectral intermediate during the inactivation of P450 
2B6 by efavirenz. Reconstituted P450 2B6 was incubated with efavirenz and difference 
scans were recorded between 350 and 700 nm for 20 minutes (the traces obtained 
between 400-500 nm are shown here).  After a baseline scan at 20 minutes, NADPH was 
added to the sample cuvette and water was added to the reference cuvette. Spectra were 
taken every 2 min. The absorbance at 400 nm was maximal at 0 time and decreased with 
























Figure 3.5 - Inactivation of P450 2B6 by 8-hydroxyefavirenz. P450 2B6 was 
inactivated by 8-hydroxyefavirenz and the activity remaining was measured using the 7-
EFC O-deethylation assay. After the addition of NADPH, aliquots were removed from 
the primary reaction mixture at 0, 5, 10, 15, and 20 min. The concentrations of 8-
hydroxyefavirenz were ( ) 0 μM, ( ) 4 μM, ( ) 5 μM, ( ) 6 μM, ( ) 8 μM, and ( ) 
10 μM. The data show the means and standard deviations from 3 separate experiments 
done in duplicate. The inset shows the double reciprocal plot of the rates of inactivation 
as a function of the 8-hydroxyefavirenz concentrations.  


















































Figure 3.6 - Inactivation of P450 2B6.4 by 8-hydroxyefavirenz. Samples were 
reconstituted and incubated with 8-hydroxyefavirenz in the presence or absence of 
NADPH as described in Methods. Inactivation was measured by determining 7-EFC O-
deethylation activity remaining. The concentrations of 8-hydroxyefavirenz were ( ) 0 
μM, ( ) 40 μM, ( ) 60 μM, ( ) 80 μM, ( ) 100 μM, and ( ) 120 μM. The data show 
the means and standard deviations from 3 separate experiments done in duplicate. The 
inset shows the double reciprocal plot of the rates of inactivation as a function of the 
8-hydroxyefavirenz concentrations. 















































Table 3.4 - Effect of incubation with 8-hydroxyefavirenz on the bupropion and 
cyclophosphamide hydroxylation activities of P450 2B6 and P450 2B6.4. Assay 
conditions were described under Methods. Data are representative of the mean and 
standard deviations of 3 separate experiments done in duplicate.  Primary reaction 
mixtures contained 8-hydroxyefavirenz at a concentration of 20 µM. 
 
Percentage of Control Activity 
Remaining 
 
Primary Reaction Conditions 
   Bupropion        Cyclophosphamide 
 
2B6 -NADPH + 8-hydroxyefavirenz 100 100 
2B6 +NADPH + 8-hydroxyefavirenz 32 ± 1 39 ± 2 
2B6.4 -NADPH + 8-hydroxyefavirenz 100 100 












Table 3.5 - Irreversibility of 2B6 inactivation by 8-hydroxyefavirenz. Assay 
conditions were as described as under Experimental Procedures. Data are representative 
of the means and standard deviations of 3 separate experiments done in duplicate. P450 
2B6 was incubated with 20 µM 8-hydroxyefavirenz for 15 min. P450 2B6.4 was 
incubated with 80 µM 8-hydroxyefavirenz for 15 min. 
 
Percentage of Control  
Primary Reaction Conditions   Activity                    P450                    HPLC 
Remaining                Remaining            Heme 
 
P450 2B6                            
+8-OHefavirenz + NADPH (B.D.) 37 ± 3 41 ± 5 35 ± 2 
+8-OHefavirenz + NADPH (A.D.) 46 ±  3 53 ± 4 43 ± 2 
P450 2B6.4    
+8-OHefavirenz + NADPH (B.D.) 47 ± 6 53 ± 5 44±5 
+8-OHefavirenz + NADPH (A.D.) 51 ± 4 55 ± 3 47 ± 4 
B.D., before dialysis 
A.D., after dialysis 
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min-1 Figure 3.6. Because the KI for inactivation of the wild-type enzyme by efavirenz (30 
μM) was greater than the KI for inactivation by 8-hydroxyefavirenz (6.4 μM), it 
suggested that the 8-hydroxy metabolite was a more potent inactivator than the parent 
compound.  Pre-incubation of the wild type and the variant enzyme with 8-
hydroxyefavirenz in the presence of NADPH also resulted in marked decreases in the 
bupropion and cyclophosphamide hydroxylation activities of both enzymes Table 3.4. 
The decrease in the enzymatic activity of the P450 2B6 that had been pre-incubated with 
8-hydroxyefavirenz when measured by its ability to hydroxylate bupropion or 
cyclosphosphamide (CPA) was reduced to 32% and 39% activity remaining, respectively.  
The decrease in the catalytic activity of the variant enzyme that had been pre-incubated 
with 20 µM 8-hydroxyefavirenz and NADPH when measured by its ability to 
hydroxylate bupropion was 81% and for CPA it was 84% as compared to untreated 
controls. The losses in bupropion and CPA hydroxylation activities were similar to the 
activity decreases observed using the 7EFC assay.  
 
Irreversibility of the inactivation of P450 2B6 and P450 2B6.4 by 8-
hydroxyefavirenz.  The changes in enzymatic activity and the losses in the CO spectra 
and heme were measured before and after overnight dialysis in samples inactivated by 8-
hydroxyefavirenz. In complete contrast to what had been observed with efavirenz, the 
inactivation of both enzymes by 8-hydroxyefavirenz was irreversible (Table 3.5).  The 
percentage of activity remaining after dialysis and after incubation with fresh reductase 
increased only slightly for both enzymes suggesting that although there may be a small 
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portion of the population of enzyme that is reversibly inactivated by 8-hydroxyefavirenz, 
the inactivation is essentially irreversible.  
 
Discussion 
 P450 2B6 is expressed in a number of organs including the liver, heart and brain, 
and has been shown to have widely variable expression levels [13-15].  P450 2B6 plays 
an important role in the metabolism a growing list of clinically important substrates 
which include bupropion, an anti-depressant and smoking cessation aid [16, 17] and 
cyclosphosphamide, an important chemotherapeutic agent [18]. Bupropion has been used 
previously as a tool to study the inactivation and inhibition of P450 2B6 [19]. It has 
recently been shown that a P450 2B6/reductase fusion protein catalyzed the metabolic 
activation of the pro-drug cyclophosphamide and markedly increased the 
cyclophosphamide-dependent cytotoxicity [20]. A number of SNPs have been found in 
the P450 2B6 gene [21] and some of these have been shown to have effects on the 
catalytic activity of the enzyme. P450 2B6*4, which corresponds to a K262R mutation of 
the protein, has recently been shown to have close to a 50% mutation frequency in 
Ghanians and close to 30% in African-Americans and Caucasians [13].  We have 
previously shown that the K262R mutant of P450 2B6 has significant effects on the 
metabolism of the P450 2B6 specific substrate bupropion [6]. In this study we have 
compared the abilities of purified P450 2B6 and its K262R mutant, 2B6.4, to metabolize 
efavirenz to 8-hydroxyefavirenz in the reconstituted system. Our data indicate that P450 
2B6.4 hydroxylates efavirenz to 8-hydroxyefavirenz at a rate almost two-fold greater than 
that of the wild-type enzyme.  The Km of the wild-type enzyme for efavirenz in the 
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present study was similar to that reported previously [2].  However, because of the 
marked variability in the expression levels of P450 2B6 in the human population, it is not 
possible to directly draw clinical conclusions based upon our current data.  In patients, 
P450 2B6 polymorphisms have been shown to have an effect on plasma levels of 
efavirenz as patients homozygous for 2B6*6 (Q172H, K262R) had higher mean plasma 
concentrations of the parent drug [4].  Two other groups have recently reported similar 
findings in patients homozygous for the 516G>T mutation (Q172H) [22, 23]. 
Because many drugs, including efavirenz, are prescribed as part of a combination 
therapy, it is important to determine which substrates may have inhibitory effects on the 
enzyme. Adverse drug reactions are a major source of hospitalizations and even mortality 
[24-26], and are defined as “an appreciably harmful or unpleasant reaction, resulting from 
an intervention related to the use of a medical product, which predicts hazard from future 
administration and warrants prevention or specific treatment, or alteration of the dosage 
regimen, or withdrawal of the product” [27].  Polymorphisms appear to play an important 
role in adverse drug reactions since many of the drugs that are frequently cited in these 
studies are metabolized by at least one polymorphic enzyme [26, 28].  We have 
previously shown that the K262R mutation protected the enzyme against inactivation by 
17-α-ethynylestradiol, which readily inactivates the wild-type enzyme [6, 29].  In the 
present study pre-incubation with efavirenz decreased the ability of P450 2B6 to catalyze 
the hydroxylation of bupropion and cyclophosphamide as well as decreasing 7-EFC O-
deethylation activity. In contrast, no effect on the above mentioned activities was 
observed with the P450 2B6.4 mutant.  The reason for the inability of the mutant to 
become inactivated by efavirenz is not clear but does not appear to involve the absence of 
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reversible binding and metabolism of efavirenz because the primary metabolite 8-
hydroxyefavirenz was generated by the mutant. We are currently investigating this 
functional difference between the wild-type and the K262R mutant enzyme, and the 
affect that this mutation has on the ability of P450 2B6 to form a reactive intermediate 
from ethynyl-containing compounds capable of inactivating the wild-type enzyme.  
Another interesting finding was that the inactivation of P450 2B6 by efavirenz 
was completely reversible after 24 hours of dialysis. A similar recovery of enzymatic 
activity has been described with purified rat P450 2B1 where the initial loss in activity 
was due to the formation of a metabolic intermediate (MI) complex [12].  MI complex 
formation results in the appearance of a characteristic maximum absorbance peak at 455 
nm in the difference spectrum [30].  A second mechanism for reversible inactivation has 
recently been described for the inactivation of P450 2E1 T303A by tert-butyl acetylene. 
In this case, the inactivation was accompanied by the appearance of a spectral 
intermediate at 485 nm [31].  Difference spectra of efavirenz-inactivated samples versus 
controls exhibited a new peak with a maximum absorbance at 435 nm.  This spectral 
intermediate formed during the inactivation by efavirenz is different than the 
intermediates reported previously. The reasons for this difference are under investigation. 
 Surprisingly, when 8-hydroxyefavirenz, the major metabolite of efavirenz, was 
used instead of efavirenz, both P450s were inactivated in a mechanism-based manner and 
the inactivation was irreversible. With either enzyme and 8-hydroxyefavirenz, we were 
unable to observe a spectral intermediate similar to that seen during the inactivation of 
the wild type enzyme by efavirenz (data not shown). These data suggest that the 
inactivation of P450 2B6 and the variant by efavirenz and 8-hydroxyefavirenz occurs 
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through two distinctly different mechanisms. Even though 8-hydroxyefavirenz is formed 
during efavirenz metabolism by both enzymes and the KI value for the hydroxylated 
product with the wild-type enzyme is approximately 4-fold lower than the KI value for 
efavirenz, the concentration of 8-hydroxyefavirenz required to achieve irreversible 
inactivation does not appear to have been achieved during the incubations. Therefore, we 
believe that during the metabolism of efavirenz in the reconstituted system, the 
concentrations of 8-hydroxyefavirenz produced contribute only negligibly to the 
inactivation. Further, the spectral intermediate that is formed during the reversible 
inactivation of P450 2B6 may be formed prior to the production of significant amounts of 
8-hydroxyefavirenz. In contrast, incubations of 2B6 with 8-hydroxyefavirenz alone may 
lead to the formation of a reactive intermediate that is not produced during incubations of 
2B6 with efavirenz alone. Our data suggest that efavirenz is initially bound in the P450 
active site in an orientation that facilitates oxidation at or near the 8-hydroxy position. 
Once the 8 position is hydroxylated, the preferred orientation of the substrate in the active 
site may bring the ethynyl moiety into closer proximity to the heme iron with the 
activated oxygen. This could then result in the generation of the reactive intermediate 
which could be responsible for the irreversible inactivation. Studies are currently 
underway to attempt to trap the reactive intermediate formed during the metabolism of 8-
hydroxyefavirenz and to obtain structural information of this intermediate. 
We also observed a difference in inactivation of P450 2B6 by 8-hydroxyefavirenz 
when compared to P450 2B6.4. The approximate KI for the wild-type enzyme was 6.4 
µM, whereas it was 75 µM for the mutant. The 12-fold greater KI for the mutant once 
again suggests that this mutation has a significant effect on the catalytic properties of the 
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enzyme. This effect was not substrate dependent as we have reported previously for 
inactivation of the mutant enzyme [6]. Similar levels of inactivation were seen with 7-
EFC, cyclophosphamide, and bupropion.  
 These studies demonstrate that the K262R mutant of P450 2B6 catalyzes the 
metabolism of efavirenz to 8-hydroxyefavirenz at a significantly greater rate than the 
wild-type enzyme. P450 2B6 in the reconstituted system was inactivated by efavirenz, 
while P450 2B6.4 was not inactivated.  Interestingly, the efavirenz-mediated inactivation 
of the wild-type enzyme was completely reversible after dialysis.  The primary 
metabolite of efavirenz, 8-hydroxyefavirenz, inactivated both enzymes and the 
inactivation was irreversible. Since the inactivation by 8-hydroxyefavirenz was 
irreversible whereas the inactivation by efavirenz was reversible, these two closely 
related compounds inactivated the enzymes through mechanisms that are completely 
different from each other. This study has further shown a difference in the catalytic 
properties of the wild-type enzyme and K262R mutant. Efavirenz and 8-
hydroxyefavirenz may prove to be useful tools for probing the structure of the P450 2B6 










1. Harris M and Montaner JS (2000) Clinical uses of non-nucleoside reverse 
transcriptase inhibitors. Rev Med Virol 10:217-29. 
 
2. Ward BA, Gorski JC, Jones DR, Hall SD, Flockhart DA and Desta Z (2003) The 
cytochrome P450 2B6 (CYP2B6) is the main catalyst of efavirenz primary and 
secondary metabolism: implication for HIV/AIDS therapy and utility of efavirenz 
as a substrate marker of CYP2B6 catalytic activity. J Pharmacol Exp Ther 
306:287-300. 
 
3. Mutlib AE, Chen H, Nemeth GA, Markwalder JA, Seitz SP, Gan LS and Christ 
DD (1999) Identification and characterization of efavirenz metabolites by liquid 
chromatography/mass spectrometry and high field NMR: species differences in 
the metabolism of efavirenz. Drug Metab Dispos 27:1319-33. 
 
4. Tsuchiya K, Gatanaga H, Tachikawa N, Teruya K, Kikuchi Y, Yoshino M, 
Kuwahara T, Shirasaka T, Kimura S and Oka S (2004) Homozygous CYP2B6 *6 
(Q172H and K262R) correlates with high plasma efavirenz concentrations in 
HIV-1 patients treated with standard efavirenz-containing regimens. Biochem 
Biophys Res Commun 319:1322-6. 
 
5. Hesse LM, von Moltke LL, Shader RI and Greenblatt DJ (2001) Ritonavir, 
efavirenz, and nelfinavir inhibit CYP2B6 activity in vitro: potential drug 
interactions with bupropion. Drug Metab Dispos 29:100-2. 
 
6. Bumpus NN, Sridar C, Kent UM and Hollenberg PF (2005) The naturally 
occurring cytochrome P450 (P450) 2B6 K262R mutant of P450 2B6 exhibits 
alterations in substrate metabolism and inactivation. Drug Metab Dispos 33:795-
802. 
 
7. Hanna IH, Reed JR, Guengerich FP and Hollenberg PF (2000) Expression of 
human cytochrome P450 2B6 in Escherichia coli: characterization of catalytic 
activity and expression levels in human liver. Arch Biochem Biophys 376:206-16. 
 
8. Hanna IH, Roberts ES and Hollenberg PF (1998) Molecular basis for the 
differences in lidocaine binding and regioselectivity of oxidation by cytochromes 
P450 2B1 and 2B2. Biochemistry 37:311-8. 
 
9. Scott EE, Spatzenegger M and Halpert JR (2001) A truncation of 2B subfamily 
cytochromes P450 yields increased expression levels, increased solubility, and 
decreased aggregation while retaining function. Arch Biochem Biophys 395:57-
68. 
 
10. Roy P, Yu LJ, Crespi CL and Waxman DJ (1999) Development of a substrate-
activity based approach to identify the major human liver P-450 catalysts of 
 75
cyclophosphamide and ifosfamide activation based on cDNA-expressed activities 
and liver microsomal P-450 profiles. Drug Metab Dispos 27:655-66. 
 
11. Harleton E, Webster M, Bumpus NN, Kent UM, Rae JM and Hollenberg PF 
(2004) Metabolism of N,N',N"-triethylenethiophosphoramide by CYP2B1 and 
CYP2B6 results in the inactivation of both isoforms by two distinct mechanisms. 
J Pharmacol Exp Ther 310:1011-9. 
 
12. Sharma U, Roberts ES and Hollenberg PF (1996) Inactivation of cytochrome 
P4502B1 by the monoamine oxidase inhibitors R-(-)-deprenyl and clorgyline. 
Drug Metab Dispos 24:669-75. 
 
13. Klein K, Lang T, Saussele T, Barbosa-Sicard E, Schunck WH, Eichelbaum M, 
Schwab M and Zanger UM (2005) Genetic variability of CYP2B6 in populations 
of African and Asian origin: allele frequencies, novel functional variants, and 
possible implications for anti-HIV therapy with efavirenz. Pharmacogenet 
Genomics 15:861-73. 
 
14. Miksys S and Tyndale RF (2004) The unique regulation of brain cytochrome 
P450 2 (CYP2) family enzymes by drugs and genetics. Drug Metab Rev 36:313-
33. 
 
15. Thum T and Borlak J (2000) Gene expression in distinct regions of the heart. 
Lancet 355:979-83. 
 
16. Faucette SR, Hawke RL, Lecluyse EL, Shord SS, Yan B, Laethem RM and 
Lindley CM (2000) Validation of bupropion hydroxylation as a selective marker 
of human cytochrome P450 2B6 catalytic activity. Drug Metab Dispos 28:1222-
30. 
 
17. Hesse LM, Venkatakrishnan K, Court MH, von Moltke LL, Duan SX, Shader RI 
and Greenblatt DJ (2000) CYP2B6 mediates the in vitro hydroxylation of 
bupropion: potential drug interactions with other antidepressants. Drug Metab 
Dispos 28:1176-83. 
 
18. Chang TK, Weber GF, Crespi CL and Waxman DJ (1993) Differential activation 
of cyclophosphamide and ifosphamide by cytochromes P-450 2B and 3A in 
human liver microsomes. Cancer Res 53:5629-37. 
 
19. Turpeinen M, Tolonen A, Uusitalo J, Jalonen J, Pelkonen O and Laine K (2005) 
Effect of clopidogrel and ticlopidine on cytochrome P450 2B6 activity as 
measured by bupropion hydroxylation. Clin Pharmacol Ther 77:553-9. 
 
20. Tychopoulos M, Corcos L, Genne P, Beaune P and de Waziers I (2005) A virus-
directed enzyme prodrug therapy (VDEPT) strategy for lung cancer using a 
 76
CYP2B6/NADPH-cytochrome P450 reductase fusion protein. Cancer Gene Ther 
12:497-508. 
 
21. Lang T, Klein K, Fischer J, Nussler AK, Neuhaus P, Hofmann U, Eichelbaum M, 
Schwab M and Zanger UM (2001) Extensive genetic polymorphism in the human 
CYP2B6 gene with impact on expression and function in human liver. 
Pharmacogenetics 11:399-415. 
 
22. Rodriguez-Novoa S, Barreiro P, Rendon A, Jimenez-Nacher I, Gonzalez-Lahoz J 
and Soriano V (2005) Influence of 516G>T polymorphisms at the gene encoding 
the CYP450-2B6 isoenzyme on efavirenz plasma concentrations in HIV-infected 
subjects. Clin Infect Dis 40:1358-61. 
 
23. Rotger M, Colombo S, Furrer H, Bleiber G, Buclin T, Lee BL, Keiser O, Biollaz 
J, Decosterd L and Telenti A (2005) Influence of CYP2B6 polymorphism on 
plasma and intracellular concentrations and toxicity of efavirenz and nevirapine in 
HIV-infected patients. Pharmacogenet Genomics 15:1-5. 
 
24. Einarson TR (1993) Drug-related hospital admissions. Ann Pharmacother 
27:832-40. 
 
25. Lazarou J, Pomeranz BH and Corey PN (1998) Incidence of adverse drug 
reactions in hospitalized patients: a meta-analysis of prospective studies. Jama 
279:1200-5. 
 
26. Pirmohamed M and Park BK (2003) Adverse drug reactions: back to the future. 
Br J Clin Pharmacol 55:486-92. 
 
27. Edwards IR and Aronson JK (2000) Adverse drug reactions: definitions, 
diagnosis, and management. Lancet 356:1255-9. 
 
28. Phillips KA, Veenstra DL, Oren E, Lee JK and Sadee W (2001) Potential role of 
pharmacogenomics in reducing adverse drug reactions: a systematic review. Jama 
286:2270-9. 
 
29. Kent UM, Mills DE, Rajnarayanan RV, Alworth WL and Hollenberg PF (2002) 
Effect of 17-alpha-ethynylestradiol on activities of cytochrome P450 2B (P450 
2B) enzymes: characterization of inactivation of P450s 2B1 and 2B6 and 
identification of metabolites. J Pharmacol Exp Ther 300:549-58. 
 
30. Chatterjee P and Franklin MR (2003) Human cytochrome p450 inhibition and 
metabolic-intermediate complex formation by goldenseal extract and its 




31. Blobaum AL, Lu Y, Kent UM, Wang S and Hollenberg PF (2004) Formation of a 
novel reversible cytochrome P450 spectral intermediate: role of threonine 303 in 







INVESTIGATION OF THE MECHANISMS UNDERLYING THE 





The cytochromes P450 (P450) are a superfamily of heme-containing 
monooxygenases that catalyze the oxidative metabolism of a number of endogenous and 
exogenous compounds, including clinically relevant drugs, pesticides and carcinogens. 
The P450 catalytic cycle consists of a number of steps including: substrate binding to 
ferric P450; reduction, as a result of the transfer of an electron from NADPH via 
NADPH-cytochrome P450 reductase (reductase); binding of molecular oxygen to ferrous 
P450, leading to the formation of oxyferrous P450; transfer of a second electron to 
oxyferrous P450 from NADPH via reductase, or in some instances cytochrome b5; 
formation of the oxygenating species; and subsequent oxidation of the substrate followed 
by product release. In addition, hydrogen peroxide can be formed via the decomposition 
of the oxyferrous complex or by autooxidation of the two-electron reduced P450 [1]. This 
phenomenon is referred to as “uncoupling”. 
Human P450 2B6 plays a major role in the metabolism of a growing list of 
compounds including bupropion, an anti-depressant and smoking cessation aid; 
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efavirenz, a non-nucleoside HIV-1 reverse transcriptase inhibitor; and cyclophosphamide, 
a chemotherapeutic prodrug that requires metabolic activativation [2-5]. Certain 
substrates of P450 2B6, such as efavirenz, are also mechanism-based inactivators of the 
enzyme. Mechanism-based inactivation occurs when a substrate, in the process of 
metabolism, is converted to a reactive intermediate that binds covalently to the active site 
of the P450, rendering it inactive [6]. A number of single nucleotide polymorphisms have 
been found in the P450 2B6 gene [7]. Recent studies in patients have demonstrated that 
some of these mutations can have significant effects on clinical outcomes [8, 9]. 
However, studies investigating the mechanisms underlying these effects are lacking. In 
order to address this issue, we have used recombinant P450 2B6 and a mutant P450 2B6 
K262R (2B6.4), which corresponds to the P450 2B6*4 variant allele observed in humans 
(785A>G, exon 5), to investigate the functional consequences of this amino acid 
mutation.  
Previously, we demonstrated that efavirenz and 17EE (Figure 4.1), which both 
inactivate P450 2B6, do not inactivate P450 2B6.4 in the reconstituted system [10, 11]. 
Further, in those studies the mutant enzyme was not able to metabolize 17EE, a substrate 
readily metabolized by the wild-type enzyme. In this study, we have systematically 
investigated some of the aspects of P450 catalytic function that could potentially be 
altered by the K262R mutation.  Therefore, we conducted studies to elucidate whether 
differences in the catalytic activities of P450 2B6 and P450 2B6.4 are related to: 1) active 
site topology; 2) substrate binding; 3) interaction with reductase; 4) reaction coupling. 
Our approach included the use of phenyldiazene to probe the active site of the P450, and 











Figure 4.1 - Chemical structures of efavirenz and 17EE. 
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HO 




equivalents from NADPH. The results presented here suggest that there may be some 
differences in the active site topologies of the two enzymes, although the binding 
constants derived from spectral binding studies were similar. Interestingly, reaction 
stoichiometry experiments revealed that the reactions catalyzed by the mutant were more 
uncoupled than the reactions catalyzed by the wild-type enzyme. The addition of 
cytochrome b5 improved the coupling of P450 2B6.4 and facilitated inactivation of the 
enzyme by both compounds. 
 
Experimental Procedures 
Materials. Benzphetamine, BSA, 17EE, catalase and NADPH were purchased from 
Sigma (St. Louis, MO). Efavirenz was purchased from Toronto Research Chemicals 
(Ontario, Canada). 7-Ethoxy-4-(trifluoromethyl)coumarin (7-EFC) was obtained from 
Molecular Probes (Eugene, OR). Phenyldiazene was purchased from Research Organics 
(Cleveland, OH). The P450 2B6 plasmid was a generous gift from Dr. James Halpert, 
University of Texas Medical Branch, Galveston, Texas. All other chemicals were of the 
highest grade commercially available.    
 
Site-Directed mutagenesis, expression and purification of P450s and Reductase.  
Construction of the P450 2B6.4 mutant was performed as described by Bumpus et al. 
[11]. P450 2B6, P450 2B6.4, and NADPH-P450 reductase were expressed in E. coli 
Topp 3 cells and purified according to published protocols [12-14]. Cytochrome b5 was 
purified from liver microsomes of phenobarbital-treated Long-Evans rats. 
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N-phenylprotoporphyrin IX regioisomer formation. The procedures used in these 
studies was adapted from published protocols [15, 16]. The phenyldiazene stock used in 
these experiments was prepared by adding 2.5 μl of neat phenyldiazene to 200 μL of 1N 
KOH. For the myoglobin experiments, 5 nmol of myoglobin in 100 mM KPi, pH 7.4, was 
placed into a 1 ml cuvette and the absorbance spectrum from 400 to 500 nm was 
recorded. Then, 3 μl of the phenyldiazene stock was added to the cuvette and the 
absorbance spectrum was once again determined. A peak was observed at 430 nm, which 
is characteristic of a myoglobin phenyl-iron complex. Once the peak reached a maximum 
(approximately 10 min), the protein was denatured by adding the contents of the cuvette 
to 5 ml of 5% sulfuric acid (aq). After sitting for 2 hours the sample was extracted twice 
with an equal volume of methylene chloride. The extract was then dried down under a 
stream of nitrogen. For the P450 experiments, 2 nmol of P450 in 100 mM KPi, pH 7.4, 
was placed into a 1 ml cuvette and the absorbance from 400-500 nm was measured. 
Then, 1.5 μl of the phenyldiazene stock solution was added to the cuvette and peak 
formation at 478 nm was monitored. After the peak formation reached a maximum 
(approximately 10 min) 3 μl of potassium ferricyanide [50 μM] was added to the cuvette 
and the contents of the cuvette were mixed and allowed to sit for 3 minutes. This was 
repeated twice to induce migration of the phenyl group from the iron to the porphyrin 
nitrogens. The sample was then denatured and extracted with methylene chloride as 
described above for myoglobin. After being dried under nitrogen, the N-
phenylprotoporphyrins were reconstituted in 150 μl of solvent A (40% water, 59.5% 
methanol, .5% acetic acid). The samples were analyzed by HPLC LC-MS using a 
Phenomenex phenyl-hexyl column under isocratic conditions with 70% A and 30% B 
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(99.5% methanol, .5% acetic acid). The area under the curve was determined for each of 
the four resulting regioisomers. These data were then expressed as a percentage of the 
total sum of the areas under the curve of all four peaks. 
 
Spectral binding. Spectral binding experiments were performed by titrating 1 μM of 
P450s 2B6 and 2B6.4 with either benzphetamine (dissolved in water) or efavirenz 
(dissolved in ethanol) at room temperature. Samples were brought to a total volume of 1 
ml using 100 mM KPi, pH 7.4, and placed into a cuvette. The reference cuvette also 
contained 1 μM of the P450s in 100 mM KPi, pH 7.4. Vehicle solvent was added to the 
reference cuvette immediately following the titration of either benzphetamine or 
efavirenz into the sample cuvette. UV-visible spectra were recorded from 350-500 nm 
following the addition of each aliquot of the ligand to the sample cuvette and an equal 
volume of the vehicle solvent to the reference. The absorbance differences between the 
maximum and minimum absorbencies observed in the difference spectrum following 
each addition were recorded and plotted against the concentrations of benzphetamine or 
efavirenz added using GraphPad Prism (GraphPad software, San Diego, CA). Spectral 
binding studies to determine the apparent Kd of reductase binding to P450 were 
performed in a similar fashion by titrating 1 μM P450 with reductase (0–8 μM) as 
previously described by French et al., [17]. Ks of benzphetamine or efavirenz binding and 
the apparent Kd value of reductase binding values were approximated by plotting the 
inverse of the absorbance changes between 390 nm and 420 nm (type I) as a function of 
the concentration of either benzphetamine or reductase, and between 436 nm and 416 as a 
function of the efavirenz concentration. 
 84 
 
Alternate oxidant studies. The alternate oxidant tert-butyl hydroperoxide (tBHP) was 
used to support P450 catalytic activity in place of NADPH, reductase and molecular 
oxygen. P450s 2B6 or 2B6.4 were placed in 50 mM KPi, pH 7.4, to a final volume of 200 
μl. An aliquot (12 μl) of this primary mixture was transferred into 990 μl of assay mixture 
that contained 100 μM 7-EFC and 40 μg BSA/ml in 50 mM potassium phosphate buffer, 
pH 7.4. The assays were performed as previously described [18]. The concentration of 
tBHP (2.5 mM) used in experiments to test for inactivation was determined to be optimal 
by measuring 7-EFC O-deethylation activity at concentrations of tBHP ranging from 0 to 
5 mM.  The presence of 2.5 mM tBHP resulted in maximum formation of the 7-EFC O-
deethylated product, with no measurable inhibition of enzyme activity. 
 
Reaction stoichiometry. P450 2B6 or P450 2B6.4 (65 pmol) was incubated with 
reductase at a 1:2 molar ratio of P450:reductase for 45 min at 4ºC. In the experiments in 
the presence of cytochrome b5, samples were reconstituted in a 1:2:1  molar ratio of 
P450:reductase:cytochrome b5. P450 and reductase were incubated together on ice for 5 
min prior to the addition of cytochrome b5. The sample was brought to a total volume of 
1 ml using 100 mM potassium phosphate buffer, pH 7.4 and placed into a cuvette. The 
sample was allowed to sit at room temperature for 3 min before the addition of NADPH 
to a final concentration of 200 μM. NADPH consumption was measured continuously, 
both in the presence and absence of substrate (10 μM 17EE or efavirenz), by monitoring 
the absorbance at 340 nm over 4 min. The concentration of NADPH was determined 
using an extinction coefficient of 6.22 mM-1cm-1 [19]. To measure product formation, 700 
μl of the sample was removed and the reaction was quenched by the addition of 300 μl of 
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acetonitrile. Since the metabolism of both efavirenz and 17EE leads to the formation of 
multiple products, substrate depletion was used to quantify product formation. For this 
reason substrate concentrations were used where depletion could be readily determined. 
The samples were analyzed by HPLC as previously described [10, 20]. The remaining 
300 μl of the sample was used to determine the amount of hydrogen peroxide formed 
using the ferrithiocyanate method [21]. 
 
Inactivation of P450 2B6.4 in the presence of cytochrome b5.  The purified P450 was 
reconstituted with reductase and cytochrome b5 as described above for 45 minutes at 4 
°C. The primary reaction mixtures contained 1 μM P450, 2 μM reductase, 1 μM 
cytochrome b5, 110 U catalase and efavirenz (0-50 µM) or 17EE (0-160 µM) in 50 mM 
potassium phosphate buffer, pH 7.4. The primary reaction mixtures were then incubated 
for 10 min at 30 °C prior to the addition of NADPH to a final concentration of 1.2 mM.  
Following the initiation of the reaction by the addition of NADPH, 12 μL aliquots were 
removed from the primary reaction mixtures at the times indicated and transferred to 990 
μL of the secondary reaction mixtures which contained 100 μM 7-EFC, 1 mM NADPH, 
and 40 μg BSA/mL in 50 mM potassium phosphate buffer, pH 7.4.  The secondary 
reaction mixtures were incubated for 10 min at 30 °C, and then quenched by the addition 
of 334 μL of acetonitrile. The amount of 7-hydroxy-4-(trifluoromethyl) coumarin formed 
was measured at room temperature using an excitation wavelength of 410 nm and an 
emission wavelength of 510 nm on a RF-5310 Spectrofluorophotometer (Shimadzu 
Scientific Instruments, Inc., Wood Dale, IL).  
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17EE metabolism. P450 2B6.4 was reconstituted together with reductase and 
cytochrome b5 as described above. The primary reaction mixture contained 1 μM P450, 2 
μM reductase, 1 μM cytochrome b5, 200 μg/ml ascorbate, 110 U catalase, 40 μM 17EE 
and 50 mM potassium phosphate buffer, pH 7.4.  The metabolites were resolved by 
reverse-phase HPLC according to a published protocol [20]. 
 
 Results 
P450 2B6 and P450 2B6.4 active site topology. Phenyldiazene forms a σ-bonded 
complex with the heme iron of the P450, resulting in the formation of a phenyl-iron 
complex. Oxidation facilitates the migration of the phenyl group to an available pyrrole 
nitrogen belonging to rings A, B, C or D. The ratio of formation of the resulting N-
protoporphyrin IX regioisomers, denoted as NA, NB, NC and ND, allow for inferences to 
be made regarding the accessibility of each of the four pyrrole rings [15, 16, 22]. 
Phenyldiazene was added to P450s 2B6 and 2B6.4, and formation of the phenyl-iron 
complex was determined spectrally by monitoring the peak formation at 478 nm and a 
concomitant decrease at 418 nm (data not shown). Following oxidation using 
ferricyanide, the samples were analyzed by LC-MS and all four N-phenylprotoporphyrin 
IX regioisomers were observed. The elution times of the resulting regioisomers were 
compared to the standards produced from the incubation of phenyldiazene with 
myoglobin (data not shown). The major product formed by the wild-type enzyme was 
NC, which accounted for 46 ± 2 % of the total regioisomer formation.  NA, NB and ND 
were also detected, and accounted for 10 ± .7 %, 7 ± .5 % and 37 ± 1 % respectively 








Figure 4.2 – P450 2B6 N-phenylprotoporphyrin IX regioisomers formation. P450 
2B6 was incubated with phenyldiazene and phenyl-iron complex formation was observed 
spectrally as described under Experimental Procedures. Oxidation caused migration of 
the phenyl to the porphyrin nitrogens. The individual peaks represent migration of the 
phenyl to pyrrole rings A (NA), B (NB), C (NC) or D (ND). The chromatogram is 
















































































Figure 4.3 – P450 2B6.4 N-phenylprotoporphyrin IX regioisomers formation. P450 
2B6.4 was incubated with phenyldiazene and phenyl-iron complex formation was 
observed spectrally as described under Experimental Procedures. Oxidation caused 
migration of the phenyl to the porphyrin nitrogens. The individual peaks represent 
migration of the phenyl to pyrrole rings A (NA), B (NB), C (NC) or D (ND). The 







the wild-type enzyme. The reaction of phenyldiazene with P450 2B6.4 also resulted in 
the formation of all four N-phenylprotoporphyrin IX regioisomers (Figure 4.3). However, 
NC only represented 37 ± 1 % of the overall formation, while NA, NB and ND constituted 
15 ± .5 %, 11 ± 3 % and 38 ± 4 %, respectively. These data suggest that there may be 
differences in the active site topologies of the two enzymes. 
 
Spectral binding of benzphetamine and efavirenz to P450 2B6 and P450 2B6.4. 
Spectrophotometric titrations were performed to investigate whether these two substrates 
of P450 2B6 and P450 2B6.4 showed differences in binding affinity to the two enzymes. 
The dissociation constants (Ks) were determined from the titration curves. Benzphetamine 
was chosen because it produces a prominent type I spectral change in P450 2B6. 
Efavirenz caused a type II spectral change, which is characteristic of a nitrogen atom 
coordinating to the heme. Both enzymes showed similar affinities for both of the 
substrates. The Ks values for benzphetamine binding to P450s 2B6 and 2B6.4 were 18 
μM and 17 μM, respectively (Table 4.1). The efavirenz spectral dissociation constants 
were also similar between the two enzymes, with a value of 85 μM for the wild-type 
enzyme and 123 μM for the variant enzyme (Table 4.1). The Ks values for 17EE binding 
could not be determined since 17EE does not induce measurable spectral shifts. These 
data on the binding of benzphetamine and efavirenz suggest that P450 2B6 and P450 
2B6.4 are able to bind substrates in a similar manner. Therefore, the differences in 


















Table 4.1 - Spectral binding of benzphetamine and efavirenz to P450 2B6 and P450 
2B6.4. P450s were titrated with benzphetamine or efavirenz until the maximum type I 
(benzphetamine) or type II (efavirenz) spectral shift was observed as described under 
Experimental Procedures. The ks values were estimated by plotting the inverse of the 
absorbance changes (average of 3 separate experiments done in duplicate) associated 
with either type I or type II binding as a function of the concentration of benzphetamine 
or efavirenz. The data are representative of 3 separate experiments performed in 
duplicate. 
 
 Substrate Ks 
2B6 Benzphetamine 18 μM 
2B6.4 Benzphetamine 17 μM 
2B6 Efavirenz 85 μM 





Inactivation of P450s by 17EE and efavirenz using an alternate oxidant. We used 
tert-butyl hydroperoxide as an activated oxygen surrogate to investigate whether the 
wild-type and/or mutant enzymes could become inactivated by 17EE or efavirenz in a 
reductase and electron-free system. tBHP produces an active iron-oxygen species with 
the P450 that can support P450 catalytic activity in the absence of molecular oxygen and  
reducing equivalents from NADPH [23]. Both P450 2B6 and P450 2B6.4 were 
inactivated by 17EE and efavirenz when tBHP was used as an oxidant. P450 2B6 7-EFC 
O-deethylation activity remaining was 52 ± 2 % when the concentration of efavirenz was 
50 μM and 32 ±1% when incubated with 80 μM efavirenz (Table 4.2). P450 2B6 was 
also inactivated by 17EE in the presence of tBHP in a concentration-dependent manner 
(Table 4.2). Interestingly, tBHP was also able to support the inactivation of P450 2B6.4 
by both compounds (Table 4.2). Thus, in a system that is not dependent upon reductase, 
NADPH and oxygen, the variant enzyme behaved in a manner similar to the wild-type 
enzyme. These data suggest that the ability of P450 2B6.4 to interact with reductase may 
be compromised. 
 
Determination of the apparent Kd of reductase binding to P450s 2B6 and 2B6.4. To 
determine whether the lack of inactivation of the mutant enzyme by 17EE and efavirenz 
in the reconstituted system was the result of impaired interaction with reductase, complex 
formation of the P450s with reductase was measured spectrophotometrically. The binding 
of reductase to P450s results in a low to high spin shift in the heme iron, characterized 
spectrally by a decrease in the absorbance at 418 nm and an increase in the absorbance at 













Table 4.2 - Inactivation of P450s 2B6 and 2B6.4 using tert-butylhydroperoxide to 
support the reaction. P450s were incubated with tBHP and the inactivators indicated as 
described in the Experimental Procedures section. Activity remaining was determined 
using the 7EFC O-deethylation assay. The data are presented as percent activity 
remaining as compared to control sample incubated with tBHP in the absence of 




Percent activity remaining 
50 μM inactivator           80 μM inactivator 
2B6 Efavirenz 52 ± 2 32 ± 1 
2B6.4 Efavirenz 66 ± 3 48 ± 1 
2B6 17EE 33 ± 1 21 ± 2 

















Table 4.3 - Determination of the apparent Kd of reductase binding to P450s 2B6 and 
2B6.4. P450 (1 μM) was added to 100 mM KPi (pH 7.4) to a final volume of 1 ml. 
Reductase (0 – 8 μM) was titrated and readings were taken following each addition. The 
apparent dissociation constant was determined by plotting the inverse of the absorbance 
changes (average of 3 separate experiments done in duplicate) between 390 nm and 420 
nm (type I) as a function of the reductase concentration.   
 
 Apparent Kd 
2B6 240 nM 




almost 4-fold greater than the value obtained from experiments with the wild-type 
enzyme (Table 4.3). This difference does not seem to be marked enough to solely account 
for the differences in catalytic activity we observed between the two enzymes since we 
routinely used reductase concentrations in excess of P450. To gain a more complete 
understanding of the catalytic activities of the two enzymes, the reaction stoichiometry 
for the metabolism of 17EE and efavirenz by P450 2B6 and P450 2B6.4 was determined.  
 
Reaction stoichiometry. As shown in Table 4.4, NADPH consumption was not 
increased by the presence of substrate when measured for either of the enzymes. During 
the metabolism of 17EE and efavirenz by P450 2B6, hydrogen peroxide was formed at a 
rate similar to the rate of product formation. In contrast, the majority of NADPH 
consumed by P450 2B6.4 resulted in the formation of hydrogen peroxide (Table 4.4).  
These data indicate that the metabolic reactions of P450 2B6.4 with 17EE and efavirenz 
are more uncoupled than the metabolism of these compounds by P450 2B6. 
 Several studies have demonstrated that cytochrome b5 can increase the coupling 
of P450 catalyzed reactions, including those involving P450 2B enzymes [24, 25]. With 
this in mind, we measured NADPH consumption, hydrogen peroxide formation and 
product formation in the presence of cytochrome b5. Reconstitution of P450 2B6.4 with 
cytochrome b5 as well as reductase dramatically improved the coupling of both reactions 
(Table 4.5). Interestingly, cytochrome b5 only had a minimal effect on the coupling of the 
wild-type reactions (Table 4.5). Further, P450 2B6.4-mediated 17EE product formation, 
as measured by substrate depletion, was observed when cytochrome b5 was present in the 












Table 4.4 - Stoichiometry for the metabolism of 17EE and efavirenz by P450s 2B6 
and 2B6.4. P450s were reconstituted with reductase as described under Experimental 
Procedures. NADPH oxidation was measured spectrally by monitoring absorbance at 340 
nm. Portions of the sample were then used to determine hydrogen peroxide and product 
formation. Product formation was measured by substrate depletion. All of the values are 
presented as nmol/nmol P450/min. 
 
P450 Substrate NADPH 
oxidation 
H2O2 formed Product 
formed 
 
2B6 No substrate 15.7±.5 2.2±.1 0  
2B6 Efavirenz 16.2±.9 6.3±.1 6.8±.2  
2B6 17EE 15.1±.6 7.8±.3 7.3±.4  
























Table 4.5 - Improvement of P450 2B6.4 reaction coupling upon reconstitution with 
cytochrome b5. P450s were reconstituted with reductase and cytochrome b5. The assay 
was performed as described under Experimental Procedures. NADPH oxidation was 
measured for 4 min then the sample was used to determine both hydrogen peroxide 
formation and product formation. All values are presented as nmol/nmol P450/min. 
 
P450 Substrate NADPH 
oxidation 
H2O2 formed Product 
formed 
 
2B6 No substrate 14.3±.4 1.8±.2 0  
2B6 Efavirenz 15.8±.7 5.6±.3 9.6±.6  
2B6 17EE 15.0±.7 6.5±.1 8.2±.4  















inactivation of P450 2B6.4 by efavirenz and 17EE could occur in the presence of 
cytochrome b5.  
 
Inactivation of P450 2B6.4 by 17EE and efavirenz in the presence of cytochrome b5. 
We previously reported that P450 2B6.4 is not inactivated by 17EE and efavirenz when 
reconstituted with reductase alone [10, 11]. Inactivation of the mutant enzyme by 17EE 
and efavirenz in the presence of cytochrome b5 was measured using the 7-EFC O-
deethylation assay. P450 2B6.4 was inactivated by efavirenz (Figure 4.4) and 17EE 
(Figure 4.5) in a time- and concentration-dependent manner and the inactivation 
exhibited an absolute requirement for NADPH.  The activity loss followed pseudo first 
order kinetics. Linear regression analysis was performed and the kinetic constants for the 
efavirenz- mediated inactivation of the mutant enzyme were determined from the inset of 
figures 4 and 5. The KI values for inactivation of P450 2B6.4 by efavirenz and 17EE 
were 30 μM and 113 μM respectively.   
 
Metabolism of 17EE by P450 2B6.4 requires cytochrome b5. Studies were conducted 
to determine which 17EE metabolites were formed during metabolism by P450 2B6.4 in 
the presence of cytochrome b5. 17EE was incubated with P450 2B6.4 that was 
reconstituted with reductase and cytochrome b5 in the presence or absence of NADPH. 
The metabolites were analyzed using reverse phase HPLC as shown in Figure 4.6. P450 
2B6.4 metabolized 17EE to give a number of major metabolites denoted as C, D and E as 
well as a minor metabolites, such as A and B. Metabolite B was not present in the 


















Figure 4.4 – Inactivation of P450 2B6.4 by efavirenz in the presence of cytochrome 
b5. The time- and concentration-dependent inactivation of P450 2B6.4 by efavirenz in the 
presence of cytochrome b5 was measured by determining the 7-EFC O-deethylation 
activity. After initiation of reaction by the addition of NADPH, aliquots were removed 
from the primary reaction mixture at 0, 5, 10, 16 and 21 minutes. The concentration of 
efavirenz were ( ) 0 μM, ( ) 10 μM, ( ) 20 μM, ( ) 40 μM, and ( ) 50 μM. The data 
show the means and standard deviations from 4 separate experiments done in duplicate. 
In some cases the standard deviations were less than the size of the symbols. The inset 
shows the double reciprocal plot of the rates of inactivation as a function of the efavirenz 
concentrations. 








































































Figure 4.5 – Inactivation of P450 2B6.4 by 17EE in the presence of cytochrome b5. 
The time- and concentration-dependent inactivation of P450 2B6.4 by 17EE was 
measured by determining the 7-EFC O-deethylation activity. After initiation of reaction 
by the addition of NADPH, aliquots were removed from the primary reaction mixture at 
0, 5, 10, 16 and 21 minutes. The concentration of efavirenz were ( ) 0 μM, ( ) 40 μM, 
( ) 80 μM, ( ) 120 μM and ( ) 160 μM. The data show the means and standard 
deviations from 4 separate experiments done in duplicate. In some cases the standard 
deviations were less than the size of the symbols. The inset shows the double reciprocal 




























Figure 4.6 – Metabolism of 17EE by P450 2B6.4 in the presence of cytochrome b5. 
Metabolites A, A1, and C are mono-hydroxylated metabolites, though the exact identities 
have not yet been determined.  Metabolite D corresponds to 2-hydroxy-17EE, metabolite 
E corresponds to estrone and F corresponds to the substrate, 17EE. We previously 
showed that in the absence of cytochrome b5 P450 2B6.4 does not readily metabolize 












P450 2B6 is involved in the metabolism of a growing number of substrates 
including drugs, pesticides and procarcinogens [26, 27] and is expressed in a number of 
organs including the liver, kidney, skin, heart and brain [28-31]. Clinical studies have 
demonstrated a large degree of inter-individual variability in the metabolism of P450 2B6 
specific substrates. Genetic polymorphisms appear to play a major role in this variability 
and a number of single nucleotide polymorphisms have been found in the P450 2B6 gene 
[32]. Several studies have shown that these polymorphisms can have clinical 
consequences. The majority of studies regarding P450 polymorphisms have focused on 
correlating patient genotypes to a particular phenotype. However, there are very few in 
vitro studies investigating the mechanisms underlying effects of these mutations. The 
goal of our studies has been to understand how a particular naturally occurring genetic 
mutation can affect the structure and function of the P450. 
We have previously demonstrated that the mutation of lysine 262 of the P450 2B6 
protein to arginine can result in marked changes in catalytic activity [10, 11]. Our 
findings that P450 2B6.4 was not inactivated by efavirenz and 17EE, known inactivators 
of the wild-type enzyme, were the most intriguing [11]. This mutant, which corresponds 
to the P450 2B6*4 variant allele of the P450 2B6 gene, is of particular interest because it 
is present in at least 3 variant alleles and has a high mutation frequency. This mutation 
has been found across all ethnic groups genotyped for P450 2B6 polymorphisms and has 
been shown to have nearly a 50% mutation frequency in Ghanians and a frequency of 
nearly 30% in African-American, Caucasian, Japanese and Taiwanese populations [32].  
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Previous studies using a number of P450s have demonstrated that phenyldiazene 
is a useful tool for gaining information about the topology of the P450 active site [22, 33, 
34]. Phenyldiazene forms a σ-bonded complex with the heme iron of the P450, resulting 
in the formation of a phenyl-iron complex. Oxidation results in the migration of the 
phenyl group to an available pyrrole nitrogen belonging to rings A, B, C or D. The ratios 
of formation of the resulting N-protoporphyrin IX regioisomers, denoted as NA, NB, NC 
and ND, allow for inferences to be made regarding the accessibility of, or open space 
above, each of the four pyrrole rings. In the case of bacterial P450 isoforms, the 
information gained using phenyldiazene has been consistent with X-ray crystallography 
data [35]. In the present study, we used phenyldiazene to investigate whether the K262R 
mutation leads to significant changes in active site topology. Although the overall 
profiles for the formation of the regioisomers were similar between the two enzymes, 
there was a difference in the migration of the phenyl group to the nitrogen of the pyrrole 
ring C. In the experiments with the wild-type enzyme, the NC regioisomer accounted for 
46% of the total formation. However, in the case of the mutant, NC formation only 
accounted for 37% of the total. Though this difference is small, it suggests that the active 
site topologies of the two enzymes differ to some extent.  
To further investigate whether there were differences in the active sites of the two 
enzymes, spectral binding studies were performed. Benzphetamine and efavirenz were 
chosen because these two substrates result in pronounced spectral changes. Other 
substrates were tested, such as 17EE, and spectral changes were not detected when these 
substrates were added to P450 2B6. The Ks values determined by measuring spectral the 
changes resulting from titration of P450s 2B6 and 2B6.4 with benzphetamine and 
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efavirenz were similar between the two enzymes, suggesting that the K262R mutation 
does not significantly affect binding. The ΔA values were similar in all cases. 
According to the P450 2B4 crystal structure, the only structure of a P450 2B 
family member currently available, residue 262 is in the G/H loop [36, 37]. Although this 
region is not in close proximity to the active site, it could potentially play a role in the 
interaction with reductase. To test whether the K262R mutation alters the ability of the 
enzyme to interact with reductase, we performed experiments to measure the ability of 
each P450 to associate with reductase. Spectral studies to investigate the association of 
the P450s with reductase suggested that the mutant may have a somewhat lower affinity 
for reductase, however, the difference between the mutant and wild-type enzymes in 
reductase binding did not seem profound enough to account for the marked differences in 
catalytic activity. In addition, we used tBHP as an oxidant to determine if the mutant 
enzyme would be catalytically similar to the wild-type in the absence of the requirement 
to interact with reductase. Interestingly, in the presence of alternate oxidants the mutant 
was readily inactivated by 17EE and efavirenz suggesting that electron transfer to P450 
2B6.4 may be compromised during these reactions when using the reconstituted system.  
In order to gain a comprehensive understanding of a particular reaction it is 
necessary to determine the stoichiometry of the reaction. Investigation of the 
stoichiometry for metabolism of 17EE and efavirenz by the two enzymes indicated that 
the mutant appeared to be more uncoupled. Coupling can be defined as the fraction of 
electrons used towards the formation of monooxygenated metabolites. Therefore, 
uncoupling refers to a decrease in monoxygenated metabolite formation and a 
concomitant increase in non-productive metabolite product formation, namely the 
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autooxidation of the oxyferrous P450 to superoxide which is converted to hydrogen 
peroxide, as well as the release of hydrogen peroxide from the peroxo-iron intermediate. 
Reaction stoichiometry relates NADPH and oxygen consumption with hydrogen peroxide 
and metabolite formation. The mutant produced more hydrogen peroxide than the wild-
type both in the presence and absence of substrate. In an attempt to improve the coupling 
of the P450 2B6.4 reactions, cytochrome b5 was added to the reconstitution mixture. The 
presence of cytochrome b5 improved the coupling of the mutant enzyme, and the 
hydrogen peroxide levels were closer to those observed for the reactions catalyzed by the 
wild-type enzyme. Further, the addition of cytochrome b5 to the reconstitution mixture 
resulted in the inactivation of P450 2B6.4 by efavirenz and 17EE.  
Cytochrome b5 is a 17-kDa heme-containing protein that is located in the 
membrane of the endoplasmic reticulum [38], and it functions as an electron donor in a 
number of reactions, including cholesterol biosynthesis and certain P450-catalyzed 
reactions [39]. Depending upon the P450 isoform and the substrate being investigated, 
cytochrome b5 has been shown to increase, inhibit, or have no effect on P450 activity 
[40]. Studies on the metabolism of methoxyflurane by P450 2B4, the rabbit isoform of 
P450 2B6, in the reconstituted system revealed that cytochrome b5  was absolutely 
required [41, 42]. Interestingly, cytochrome b5 had no effect on P450 2B4-mediated 
metabolism of benzphetamine [43]. There are two primary hypotheses to explain the 
stimulatory effect of cytochrome b5 on some P450-mediated reactions. The first is that 
reduced cytochrome b5 donates the second electron in the catalytic cycle to the P450 [44-
46]. This is supported by studies showing electron transfer from cytochrome b5 to P450 as 
well as the observation that “uncoupling” is decreased in the presence of the b5 protein 
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[25]. In the latter instance, the presence of cytochrome b5 results in a decrease in 
hydrogen peroxide formation and a subsequent increase in product formation, possibly by 
stabilizing the oxyferrous P450 complex, leading to a decrease in release of superoxide 
[25]. The second hypothesis is that cytochrome b5 physically interacts with the P450 
causing a conformational change that facilitates interaction with the substrate or 
reductase. This notion is supported by studies where the apo-cytochrome b5, which 
cannot be reduced and donate the second electron, was able to stimulate P450-catalyzed 
reactions [47]. However, the exact role of cytochrome b5 in P450-dependent 
hydroxylation and oxidations is unclear. In our studies, cytochrome b5 improved the 
coupling of the mutant enzyme, facilitating metabolism of 17EE by the mutant and 
inactivation by both compounds. This suggests that for these particular reactions the 
former hypothesis may be true. We performed studies using both apo-cytochrome b5 and 
Mn-cytochrome b5, which cannot act as an electron donor, and did not see any 
improvement in the catalytic activity of P450 2B6.4 (data not shown). Studies performed 
by Zhang et al., under single turnover conditions demonstrate that cytochrome b5 and 
reductase donate the second electron to the P450 (in this case P450 2B4) at a similar rate, 
however catalysis occurs faster in the presence of cytochrome b5 [48]. These authors 
hypothesize that the conformation of the oxyferrous P450 may be different in the 
presence of cytochrome b5 and reductase. This proposal is a potential explanation for the 
findings reported in the present study. However, it is also possible that the oxyferrous 
P450 2B6.4 and/or peroxo-iron intermediate in the presence of 17EE and efavirenz are 
less stable than the same complexes formed by the wild-type enzyme. Further studies are 
necessary to elucidate the precise mechanism by which cytochrome b5 increases the 
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catalytic activity of P450 2B6.4. These studies could potentially include measuring the 
formation and stability of the oxyferrous complex of P450 2B6.4 versus P450 2B6.  
In summary, we have investigated the effects of the K262R mutation on active 
site topology, substrate binding, interaction with reductase and reaction stoichiometry. 
The inactivation of P450 2B6.4 by efavirenz and 17EE showed an absolute requirement 
for cytochrome b5. In the presence of cytochrome b5, the reactions catalyzed by the 
mutant enzyme exhibited improved coupling. These studies provide evidence that the 
differences in the catalytic properties of P450 2B6 and P450 2B6.4 are related to 
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CROSS-LINKING OF CYTOCHROME P450 2B6 TO NADPH-CYTOCHROME 





The cytochrome P450 (P450) enzymes belong to a family of heme containing 
proteins that catalyze the metabolism of a wide range of endogenous and exogenous 
substrates. P450s are involved in the oxidative, peroxidative, and reductive metabolism of 
a variety of structurally diverse compounds. All P450s share a common catalytic 
mechanism which involves the two-electron reduction of molecular oxygen resulting in 
the formation of a reactive oxygen intermediate and water [1]. Electrons are transferred 
from NADPH to the P450 via NADPH-P450-reductase (reductase), which leads to the 
reductive activation of molecular oxygen followed by the insertion of one oxygen atom 
into the substrate [1]. 
Human P450 2B6 has received increased attention in recent years in part due to its 
expression in a number of extrahepatic tissues, as well as its role in the oxidative 
metabolism of a growing list of xenobiotics. However, as the crystal structure of P450 
2B6 is yet to be solved, structural information regarding this enzyme is lacking. Many of 
the inferences that have been made relating to P450 2B6 structure and function have 
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been drawn from knowledge of the rabbit isoform P450 2B4. Crystal structures of both 
the open and closed forms of P450 2B4 are available and these data have helped to 
confirm mutagenesis data that identified residues of the P450 reported to be responsible 
for the interaction with reductase [2, 3]. The interaction between P450 and reductase is 
electrostatic, involving basic residues on the P450 and acidic residues on the surface of 
reductase [4, 5]. Mutation of 25 amino acids on the surface of P450 2B4 to alanines by 
Bridges et al., revealed that residues in the C helix, as well as R422 near the β bulge and 
R443 in the L helix play a role in the interaction of the P450 with reductase [6]. 
Unfortunately, similar studies have not been performed for P450 2B6. Therefore, we 
aimed to identify the P450 2B6 residues that may be involved in the interaction with 
reductase. To approach this, we used the water soluble carbodiimide, 1-ethyl-3-(3-
dimethylaminopropyl)carbodiimide (EDC) as a crosslinker. EDC has been shown to be a 
useful tool in the identification of sites of interaction between proteins in a number of 
protein-protein complexes, including reductase-cytochrome c and P450 2E1-b5 [7, 8]. 
However, a previous attempt to cross-link P450 2B4 to reductase using EDC was 
reported to be unsuccessful [9]. In the present study, we were able to cross-link P450 2B6 
to reductase and to structurally characterize this complex. EDC covalently links lysine 
residues to either aspartic or glutamic acid residues, making this an appropriate cross-
linker to use in these studies since the interactions between the P450 and reductase are 
believed to be electrostatic.  
In order to identify P450 2B6-reductase cross-linked peptides we used 18O-water 
to isotopically label cross-linked peptides. Proteolysis by an enzyme such as trypsin, 
results in the ability of the tryptic peptides to specifically exchange oxygen atoms from 
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water with the two oxygen atoms of the carboxyl terminus [10].  By comparing the 
masses of proteolytic peptides after exchange with either 18O-water or 16O-water, cross-
linked peptides can be identified based on the magnitude of the mass shift due to the 
incorporation of two 18O atoms. The incorporation of two 18O atoms into the carboxyl 
terminus of a peptide will result in a 4 Da mass shift. Therefore, if two peptides are cross-
linked, the observed mass shift would be 8 Da, since the complex should consist of two 
linked peptides, each with a C-terminus capable of incorporating two of the 18O atoms. 
Also, incomplete incorporation can occur where cross-linked peptides may only 
incorporate three 18O atoms. In this case a 6 Da mass shift would be observed. This 
method has been used previously to identify cross-linked peptides [7, 11, 12]. The studies 




Materials. EDC was purchased from Pierce (Rockford, IL). Efavirenz was purchased 
from Toronto Research Chemicals (Toronto, Canada). 
 
Expression and purification of P450 2B6 and reductase. P450 2B6 and NADPH-P450 
reductase were expressed in E. coli Topp 3 cells and purified according to published 
protocols [13-15].  
 
Cross-linking reactions. P450 2B6, reductase and DLPC were reconstituted by 
incubating all three components at 4ºC for 45 minutes using a molar ratio of 1:1:600, 
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respectively. The components were then allowed to sit at room temperature for 10 
minutes. EDC was added to a final concentration of 10 mM from a 100 mM stock made 
fresh just prior to the experiment. After 2 hours, the reaction was quenched by dialysis 
against 100 mM ammonium bicarbonate buffer, pH 8.5 at 4ºC. 
 
Activity assay. In order to isolate the cross-linked complex, the free P450 as well as free 
reductase had to be removed from the sample. To do this, we used affinity purification 
techniques. The P450 2B6 used in these studies was his-tagged; therefore, we applied the 
cross-linked sample to a nickel column. Only P450 2B6 or the P450 2B6-crosslinked 
complex should bind to the column. Therefore, once the column was eluted and the 
contents collected, free reductase was absent from the sample. In order to remove the free 
P450 2B6, the sample was then bound to an ADP-sepharose column which binds 
NADPH binding domains. Following the use of both of these columns, only the cross-
linked complex was present. The efavirenz metabolism assay was then carried out 
according to Bumpus et al., 2006 [16]. 
 
Proteolytic digestions. The in-gel digestions as well as analyses using MALDI 
TOF/TOF were performed by the Michigan Proteome Consortium (Ann Arbor, 
Michigan) according to the protocol posted on their website 
(www.proteomeconsortium.org). For the in-solution digests and isotopic labeleling, the 
cross-linked sample was dialyzed against 100 mM ammonium bicarbonate, pH 8.5, twice 
for four hours. Trypsin was then added such that the amount of protein from the EDC 
reaction was in 50-fold molar excess. The digestion was allowed to proceed for 24 hours 
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at 37ºC. Subsequently, the samples were divided into two portions and dried using a 
SpeedVac. The resulting peptides were then reconstituted using either 16O-water or 18O-
water and analyzed using a LTQ mass spectrometer (ThermoElectron Finnigan) in the 
University of Michigan Biomedical Mass Spectrometry Facility. 
 
Data analysis. Data were analyzed using the Pro-CrossLink Version 1 suite of software 




P450 2B6 and reductase complex formation. Cross-linking of P450 2B6 to reductase 
was analyzed using SDS-PAGE. Upon incubation with EDC, reductase and P450 form a 
1:1 complex as illustrated by a band at approximately 130 kDa in the sample containing 
both enzymes (Figure 5.1, circled). This complex was absent in the control samples 
consisting of P450 or reductase (Figure 5.1) alone incubated with EDC. Interestingly, 
P450 2B6-P450 2B6 complexes were also observed as well as reductase-reductase 
complexes (Figure 5.1). However, in the absence of EDC none of the abovementioned 
complexes were formed (data not shown). The presence of both P450 2B6 and reductase 
in the 130 kDa complex was confirmed unequivocally following digestion of the excised 
band. Polypeptide chains from both P450 2B6 and reductase were identified in the digest 



































Figure 5.1 – SDS-PAGE analysis of cross-linked complexes. P450 2B6 (54 kDa), 
reductase (77 kDa) and P450 2B6 reconstituted with reductase in the presence of lipid 
(this sample was divided in half) were all incubated separately with EDC as described 
under Experimental Procedures. The gel was stained with Sypro Ruby. The circled band 
represents the cross-linked P450 2B6-reductase complex at approximately 130 kDa. This 
band was excised, digested and analyzed by mass spectrometry, which confirmed the 














Determination of the cross-linked P450 2B6-reductase complex as functionally 
active. In order to determine whether the cross-linked P450 2B6-reductase complex 
observed exists in a functional conformation, the complex was separated from the non-
cross-linked proteins by column chromatography and activity assays were performed. 
SDS-PAGE followed by coomassie staining showed that the cross-linked complex was 
the only protein remaining in the sample following the separation procedures (data not 
shown). As shown in Table 5.1, the isolated cross-linked complex was able to metabolize 
the P450 2B6 substrate efavirenz. The data obtained were normalized to total protein in 
the sample using a BCA protein assay (Pierce).  However, the metabolite formation by 
the isolated cross-linked complex was approximately 30% less than that of reconstituted 
P450 2B6 and reductase that were not incubated with EDC. The 8-hydroxyefavirenz 
formed by the non-crosslinked sample was approximately 3.7 pmol 8-
hydroxyefavirenz/mg protein, while product formation by the cross-linked sample was 
approximately 2.6 pmol 8-hydroxyefavirenz/mg protein.  
 
Mass spectrometric analysis of peptides. The identification of the cross-linked peptides 
from the P450 2B6-reductase was approached in two ways. First, peptides resulting from 
the in-gel digests of P450 2B6 alone, reductase alone and P450 2B6-reductase all 
incubated with EDC were analyzed using a MALDI TOF/TOF mass spectrometer. Since 
inter- and intra-molecular cross-links between P450 and reductase are possible, the 
peptide masses found in the P450 2B6 and reductase alone samples were subtracted from 















Table 5.1 – Determination of cross-linked P450 2B6 and reductase activity. P450 
2B6 and reductase were reconstituted in the presence of lipid as described under 
Experimental Procedures. 8-hydroxyefavirenz formation was measured and normalized 
to total protein as determined by performing a BCA protein assay. 
 
          pmol 8-hydroxyefavirenz/mg protein 
2B6 + reductase - EDC 3.7 ± 0.5 




sample. The tandem mass spectra (MS/MS) of the peptides present in the P450 2B6-
reductase sample and not in the controls, were input into the Pro-CrossLink software 
which subsequently identified a peptide with a mass of 3809.4 Da as a cross-linked 
peptide (data not shown). To confirm this identification, we took a second approach 
where we isotopically labeled the peptides with 18O water following proteolytic digestion, 
as described under Experimental Procedures. The samples were then analyzed using an 
LTQ equipped with a photodiode array detector. Figures 5.2 and Figure 5.3 show the 
respresentative UV spectra (280 nm) and total ion chromatograms, respectively, of 
peptides reconstituted in either 16O-water or 18O-water. Under electrospray ionization 
conditions, peptide ions can exist in multiple charge states. In this case, the expected 
mass shift of the precursor ion is dependent upon the charge state of the ion. For instance, 
a singly charged ion upon the incorporation of four 18O atoms would have a mass shift of 
8 Da. However, a mass shift of 4 Da would be observed for a doubly charged ion. 
Through the use of the Pro-CrossLink software, as well as manually searching through 
the mass spectra, a cross-linked peptide candidate was identified with its quintuply 
charged ion at m/z 762.6 in the 16O-water samples and at m/z 763.8 in the 18O-water 
samples; an ion at m/z 763.8 was not observed in the 16O-water sample. Figure 5.4 shows 
the co-elution of these ions in the total ion chromatograms. This mass shift of 1.2 for the 
quintuply charged ion indicates the incorporation of three 18O atoms at the C-terminus of 
this peptide. Since incomplete incorporation and/or back exchange can occur, peptides 
with a mass shift commensurate with the incorporation of three or four 18O atoms were 
considered cross-linked peptide candidates. The measured peptide mass matched the 









Figure 5.2 – UV spectra of cross-linked P450 2B6-reductase peptides reconstituted  
in 16O-water or 18O-water. P450 2B6 and reductase were reconstituted, then incubated 
with EDC as described under Experimental Procedures. In-solution digests were then 
performed and the samples were dried down using a SpeedVac. The dried peptides were 
there reconstituted in either 16O-water or 18O-water. The figure shows the peptides 
monitored at 280 nm. 
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Figure 5.3 – Total ion chromatograms of digested cross-linked P450 and reductase.  
P450 2B6 and reductase were cross-linked as described under Experimental Procedures. 
In-solution digests were then performed and the samples were dried down using a 
SpeedVac. The dried peptides were there reconstituted in either 16O-water or 18O-water. 
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Figure 5.4 – Co-elution of the quintuply charged ion at m/z 762.6 and m/z 763.8. 
Mass spectra of cross-linked peptides were analyzed manually and using the Pro-
CrossLink software to determine mass shifts between the 16O-water and 18O-water 
reconstituted samples. The mass shift of 1.2 Da for the quintuply charged ion indicates 
the incorporation of three 18O atoms at the C-terminus of this peptide. The ion at m/z 
763.8 was not present in the 18O-water sample. 
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Using the Pro-CrossLink software, the cross-linked peptide (P450 2B6: DFGMGKR)-
(reductase: RHILAILQDCPSLRPPIDHLCELLPR) was identified based upon the mass 
and charge state of the monoisotopic peak at m/z 762.6, as well as the MS/MS spectrum 
of this ion. De novo sequencing of the peptide using the MS/MS spectrum suggests that 
this may be the identity of the peptide (Figure 5.5). 
 
Discussion 
Structural information pertaining to P450 2B6 is seriously lacking, particularly 
with regard to interactions with redox partners. To address this, we have cross-linked 
P450 2B6 to reductase and have structurally characterized the resulting complex. Cross-
linking coupled with mass spectrometry is a powerful tool for elucidating sites of 
interaction between two proteins. The use of isotopic labeling during this process assists 
in unambiguous identification of cross-linked peptides. To facilitate the identification of 
as many peptide candidates as possible, conditions for 18O incorporation were optimized. 
During preliminary experiments it was determined that in-solution proteolysis resulted in 
more complete incorporation of 18O atoms compared to in-gel digestion. Further, instead 
of using the isotopic label during proteolysis, we performed the proteolysis in 16O water, 
dried the sample down using a SpeedVac and reconstituted the sample in 18O water [10]. 
This resulted in increased incorporation of 18O atoms, and potentially less back exchange.  
We have used two different approaches to identify the potential sites of 
interaction between P450 2B6 and reductase. Since EDC covalently links basic and 









Figure 5.5 – MS/MS spectrum of the precursor ion [M+5]5+ = 762.0. The cross-linked  
candidate ion was fragmented for MS/MS using an LTQ mass spectrometer. De novo 
sequencing was used to determine the potential amino acid sequence of the peptide as 
shown above. Y and b ions identified in the spectrum are shown above. The ions denoted 
as α refer to P450 from P450 2B6 peptide D134-R140. The ions denoted as β are derived 
from the reductase peptide R428-R453. Residues underlined and in bold above the figure 
represent amino acids identified in the spectrum. 

































P450 2B6: DFGMGKR Reductase: RHILAILQDCPSLRPPIDHLCELLPR 
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for the identification of amino acids involved in an electrostatic interaction. Further, we 
performed the cross-linking reaction in the presence of lipid using both full-length P450 
2B6 and reductase in order to simulate the actual physiological interaction as closely as 
possible. However, it is possible to generate false-positive cross-linked peptides which 
may not actually represent the binding orientations of the two proteins. For this reason, 
we attempted to isolate the complex and perform an activity assay to determine whether 
or not this complex was functional. Oxidative metabolism of efavirenz was observed, 
however, we cannot be certain that the cross-linked population is homogenous with 
respect to the sites of cross-linking and that the product formation can actually be 
attributed to the complex that was bound through the regions found in our studies. 
 The peptide that we have identified in the present study includes P450 2B6 
residues believed to be in the C-helix (based upon the P450 2B4 crystal structure) and 
reductase residues that lie in the connecting domain between the FAD and FMN domains. 
The same residues in the C-helix of P450 2B4 have been demonstrated by Bridges et al., 
to be involved in the interaction between the P450 and reductase [6]. When these authors 
mutated lysine 139 to alanine, the apparent Kd for reductase binding increased 23-fold. 
Since EDC cross-linked lysines to glutamic or aspartic acid residues, we propose that 
K139 is the P450 residue that is cross-linked residue in our system. Several reductase 
residues have been proposed to interact with P450s based upon mutagenesis data; 
however, all of these residues are located within the FMN domain [4, 18]. During 
reductase-mediated reduction of P450, the electrons are believed to be transferred via the 
FMN domain to the P450. Other proteins that are reduced by reductase, such as heme 
oxygenase, interact with regions of reductase other than the FMN domain [19]. With this 
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in mind, it is plausible that the specificity for the site of interaction of the reductase with 
the P450 may be more related to the structure of the P450 than that of reductase. The 
reductase amino acids (428-453) identified by our cross-linking studies are within the 
connecting domain. Although the connecting domain has not been shown to interact with 
P450, the residues do appear to be on the surface of the protein based upon the reductase 
crystal structure and, thus, would be logical candidates for interaction [20]. However, it is 
possible that this cross-linked peptide was simply more abundant, or perhaps ionized 
more readily, than other existing cross-linked peptides.  
During our analysis, two other precursor ions were identified as potential cross-
linked peptides as a result of their mass shifts in the 18O sample; unfortunately, we were 
not able to generate MS/MS data regarding these peptides. However, since the peptide 
data for the P450 cross-linking site coincides precisely with the mutagenesis data, it is 
possible that the complex characterized is biologically relevant. Further, multiple binding 
orientations may have the ability to facilitate electron transfer. Subsequent studies, such 
as mutagenesis of lysine 139 in P450 2B6, are necessary to determine whether the 
identified residues actually play a role in the interaction between the two proteins. 
Ultimately, co-crystallization of P450 with reductase may provide the most useful 
insights into the sites of interaction. 
 In summary, we have identified a P450 2B6-reductase cross-linked peptide using 
mass spectrometry coupled with isotopic labeling. This study provides the first direct 
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In the clinical setting, P450 inhibition can result in elevated plasma levels of other 
drugs that are primarily metabolized by the particular P450 being inhibited. As a result, 
inhibition of P450s has the potential to cause severe adverse events, particularly if the co-
administered drug has a narrow therapeutic index. Since mechanism-based inactivation of 
P450s is irreversible, in order to regain catalytic activity, the inactivated P450 has to be 
replaced by newly synthesized P450. The mechanism-based inactivation has a much 
greater potential to lead to drug-drug interactions than reversible inhibition [1]. A number 
of clinically relevant drugs and dietary components have been shown to be mechanism-
based inactivators in vitro. Clinical studies have confirmed that some of these 
mechanism-based inactivators affect the pharmacokinetics of co-administered drugs. 
Certain mechanism-based inactivators of P450 2B6 have been shown to cause drug-drug 
interactions including, bergamottin and 17EE. The effect of grapefruit juice on the 
pharmacokinetics of prescription drugs has received significant attention, since patients 
who ingest grapefruit juice as part of their diets exhibit significantly greater mean oral 
bioavailability of drugs belonging to several different classes, including lipid-lowering 
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drugs, calcium channel blockers and immunosuppressive agents [2, 3]. An effect of 
grapefruit juice has been reported on both the pharmacokinetics and metabolism profiles 
of more than 40 drugs [4]. These effects have been attributed to mechanism-based 
inactivation of P450s, including P450 2B6, by bergamottin a furanocoumarin present in 
grapefruit juice. The P450 2B6 inactivator 17EE has been reported to interact with a 
variety of co-administered drugs; however, the most striking interaction described thus 
far comes from a study with selegiline [5]. Selegiline is a selective, irreversible inhibitor 
of monoamine oxidase-B used in the treatment of Parkinson’s disease, and is extensively 
metabolized by P450s 2B6 and 2C19 [6]. Healthy female volunteers taking 17EE and 
selegiline concomitantly exhibited a 20-fold increase in the selegiline AUC and a 
decrease in the formation of metabolites [5]. Although, a two-fold or greater increase in 
drug plasma concentration significantly increases the risk of adverse events [7], less 
dramatic changes in plasma concentrations may still be clinically relevant if the co-
administered compound has a narrow therapeutic index. Further, the outcomes of drug-
diet and drug-drug interactions may vary depending on the age of the patient, gender, 
pathological conditions and genetic polymorphisms. With this in mind, the effects of a 
prominent P450 2B6 polymorphism (K262R; P450 2B6.4) on mechanism-based 
inactivation were studied. 
 Initial studies to investigate the effects of the K262R mutation were performed 
using bupropion as a probe substrate, since there was clinical evidence that this mutation 
caused an increase in plasma concentrations of hydroxybupropion, the pharmacologically 
active metabolite of bupropion [8]. Our studies, summarized in Chapter 2 were thus 
commensurate with the clinical data in demonstrating that the purified enzyme in the 
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reconstituted system could potentially mimic catalytic activity observed in humans [9]. 
To further probe the effects of this mutation, several structurally unrelated mechanism-
based inactivators were used. To our knowledge, the studies in this thesis were the first to 
examine the effects of a P450 genetic polymorphism on mechanism-based inactivation 
either in vitro or in vivo. The mutant enzyme was inactivated by tTEPA and bergamottin 
with KI values that were very similar to those observed for the wild-type enzyme. 
Interestingly, P450 2B6.4 was not inactivated by 17-α-ethynylestradiol, which readily 
inactivates wild-type P450 2B6 [10]. Subsequent metabolism studies revealed that the 
mutant enzyme did not metabolize 17EE. This finding led us to question whether the lack 
of inactivation of the mutant enzyme by 17EE was specific for 17EE, or whether there 
were other inactivators that would produce similar results. 
 Efavirenz, which has been shown to be a P450 2B6 specific substrate, was shown 
to inhibit P450 2B6 activity in human liver microsomes in studies using only one 
concentration and one time point [11]. Therefore, we investigated efavirenz as a 
mechanism-based inactivator of P450 2B6 and/or P450 2B6.4. As described in Chapter 3, 
efavirenz inactivated P450 2B6 in a time-, concentration-, and NADPH-dependent 
manner and the losses in activity exhibited pseudo-first order kinetics [12]. However, one 
of the generally accepted hallmarks of mechanism-based inactivation is that it is 
irreversible and the efavirenz-dependent inactivation observed in the present studies was 
reversible after 24 hours of dialysis. P450 2B6.4 was not inactivated by efavirenz, 
although the mutant enzyme metabolized efavirenz to its primary metabolite, 8-
hydroxyefavirenz. These data suggested that P450 2B6.4 was not able to produce the 
metabolite or “inactivating intermediate” responsible for the inactivation of the wild-type 
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enzyme. A number of experiments were performed in attempts to identify the reactive 
metabolite responsible for inactivation including analyzing metabolites formed during 
inactivation using an Orbitrap mass spectrometer, which provides exact mass information 
and is a powerful tool for metabolite identification. Using this instrument, a di-
hydroxylated metabolite was detected; however, the tandem mass spectrometry data was 
inconclusive, leading to the use of liquid chromatography NMR in an attempt to obtain 
precise identification of the reactive intermediate. Unfortunately, enough metabolite 
could not be collected to permit unequivocal identification of the metabolite. Since the 
metabolite of efavirenz, 8-hydroxyefavirenz was available in the lab, we also investigated 
whether the metabolite itself could inactivate the P450s. Similar to the parent compound, 
8-hydroxyefavirenz inactivated the wild-type enzyme in a time-, concentration-, and 
NADPH-dependent matter. However, in this instance the inactivation was irreversible. 
This finding was significant, since it demonstrates for the first time that a metabolite can 
inactivate a P450 through a different mechanism than the parent compound. In addition, 
the mutant enzyme was inactivated by 8-hydroxyefavirenz, suggesting that the 
inactivation occurs by a mechanism distinct from that by which the parent compound 
caused inactivation. 
  Since P450 2B6.4 exhibited marked differences in catalytic activity from the 
wild-type P450 2B6, the experiments in Chapter 4 were designed to try to elucidate the 
mechanism(s) underlying the observed differences. We systematically investigated the 
individual steps in the P450 catalytic cycle in order to determine which one(s) might be 
affected during catalysis by the mutant enzyme. Since the data from our studies with 
17EE and efavirenz were the most intriguing, we focused our mechanistic studies on 
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these two compounds. The first step was to determine whether the effects of the mutation 
could be related to changes in the active site structure. Studies using phenyldiazene to 
label the heme and spectral binding studies, respectively, indicated that both the active 
site topology and substrate binding to the active site were similar between the two 
enzymes. Analysis of the crystal structure of P450 2B4, the rabbit isoform of P450 2B6, 
suggests that the K262R mutation may lie in the G/H loop [13, 14]. It has been postulated 
that the G/H loop may be involved in the interaction between the P450 and its redox 
partners, suggesting that this mutation could affect the binding of reductase to the P450. 
However, spectral studies measuring the low to high spin shift that results from reductase 
binding indicated that P450 2B6.4 associates with reductase in a manner similar to P450 
2B6 and exhibits a similar binding affinity. In order to gain a more complete 
understanding of the similarities and differences between the two enzymes, we 
determined the reaction stoichiometries for the metabolism of efavirenz and 17EE. These 
data revealed that the mutant enzyme was more uncoupled than the wild-type. Coupling 
is generally defined as those electrons from NADPH that are used by the enzyme to 
produce monooxygenated metabolites. Conversely, uncoupling refers to those electrons 
from NADPH that are consumed and do not lead to the formation of monooxygenated 
metabolites but result in the formation of non-monoxygenated metabolite products, such 
as superoxide, hydrogen peroxide and water. The primary product produced during the 
metabolism of 17EE and efavirenz by the mutant was hydrogen peroxide. The hydrogen 
peroxide can either originate from the decomposition of the oxyferrous P450 or from 
hydrogen peroxide shunting from the peroxo-iron intermediate. Interestingly, the addition 
of cytochrome b5 resulted in increased coupling of the P450 2B6.4-catalyzed reactions, 
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with little effect on the coupling of the P450 2B6 wild-type-catalyzed reactions. Alhough 
the mechanism by which cytochrome b5 enhances reaction coupling is unclear, studies 
performed by Zhang et al. under single turnover conditions demonstrate that cytochrome 
b5 and reductase donate the second electron to the P450 (in this case P450 2B4) at a 
similar rate, however catalysis occurs faster in the presence of cytochrome b5 [15]. These 
authors hypothesize that the conformation of the oxyferrous P450 may be different in the 
presence of cytochrome b5 and reductase thereby favoring the formation of 
monoxygenated metabolites as opposed to the products associated with uncoupling. This 
hypothesis could potentially explain the findings in the present study. Taken together, 
these data demonstrate that P450 2B6.4 exhibits differences in catalytic activity from the 
wild-type and that these differences are substrate dependent. Further, the results 
presented here demonstrate for the first time the effect of a genetic polymorphism on 
individual steps in the P450 catalytic cycle.  
 Although it is believed that proximal surface residues of P450s are involved in 
interactions with the reductase, studies have not been performed to determine the specific 
site(s) of interaction between P450 2B6 and reductase [16, 17]. The studies described in 
Chapter 5 were designed to investigate the site(s) of interaction between P450 2B6 and 
reductase using the cross-linker EDC. The resulting cross-linked complex was 
structurally characterized using mass spectrometry. With this approach, we have 
identified a cross-linked peptide that appears to contain residues that lie within the C-
helix of P450 2B6 and residues from the reductase connecting domain. The spatial 
locations of these residues in the proteins are based upon the crystal structures of P450 
2B4 and reductase [13, 14, 18]. Although the reductase connecting domain has not 
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previously been implicated in its interaction with P450s, the P450 residues identified 
coincide with amino acids that have been previously shown to interact with reductase 
[16]. In order to determine whether the binding orientations of P450 2B6 and reductase in 
the cross-linked complex were physiologically relevant, we performed the cross-linking 
in the presence of lipid and isolated the cross-linked complex to assay for activity. The 
cross-linked P450 2B6 and reductase readily metabolized efavirenz to 8-
hydroxyefavirenz, indicating that P450 2B6-reductase cross-linked species that we 
identified exists in a functional conformation. These studies provide the first information 
about the potential site(s) of interaction between P450 2B6 and reductase. 
 
Future directions 
 The work in this thesis has raised a number of interesting questions that should be 
addressed in the future. Of particular interest will be determining whether the amino acids 
in the peptide identified through the cross-linking studies are actually involved in the 
interaction with reductase. These studies could include mutagenesis and competition 
studies using synthetic peptides. Also, we believe that there are potentially other cross-
linked complexes yet to be identified. To address this, studies should be performed to 
optimize cross-linking efficiency. The use of higher concentrations of P450 2B6 and 
reductase could also increase the abundance of other cross-linked complexes. It would 
also be interesting to repeat these studies using cytochrome b5 to determine whether the 
binding sites to both the P450 and reductase overlap. 
 The mechanistic studies suggested that the formation of the oxyferrous and/or 
peroxo-iron intermediates may be different between the K262R mutant and the wild-type 
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P450 2B6. Stopped flow spectroscopy studies investigating the rates of decomposition of 
the oxyferrous intermediate may help to answer this question. Ultimately, more detailed 
structural characterization of the two proteins using various techniques such as 
crystallization, hydrogen/deuterium exchange and in-solution NMR will be necessary to 
provide more conclusive insights into the differences between the two enzymes.  
 Finally, since very little information is currently available regarding the P450 2B6 
active site, the identification of the site of adduct formation and the reactive intermediate 
responsible for the inactivation of P450 2B6 could be very useful. Since efavirenz and 8-
hydroxefavirenz appear to inactivate the enzyme through distinct pathways, more 
detailed information regarding the amino acid modified and mechanisms underlying the 
inactivation by these two compounds could lead to the generation of improved P450 2B6 
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